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1. INTRODUCTION 
(Khachane K.N. et al.. 2011, Shalin A. Modi, et al..2011) 
Oral route has been one of the most popular routes of drug delivery dueto its 
easeof administration, patience compliance and least sterility constraints and flexible 
design of dosage forms. Time release technology, also known as sustained-release 
(SR), sustained-action (SA), extended-release(ER), time-release ortimed-release, 
controlled-release(CR), modifiedrelease (MR) or continuous-release (CR), is a 
mechanism used in pill tablets or capsules to dissolve slowly and release a drug 
overaprolong period oftime. Different polymers are employed dueto their insitugel 
forming characteristics and their ability to release entrapped drug in the specific 
medium by swelling and cross-linking. Hydrophilic polymer matrix is widely used for 
formulating an SRdosageform. Because of increased complication and expense 
involved in marketing of newdrug entities, has focused greater attention on 
development of sustained release or controlled releasedrug delivery system. Matrix 
system is widely used for the purpose of sustainedrelease. Infact, a matrix is defined as 
a well-mixed composite of one or more drugs with gelling agent i.e. hydrophilic 
polymers. By the sustained release method therapeutically effective concentration can 
be achieved in the systemic circulation over an extended period of time, thus 
achieving better compliance of patients. Sustained release dosage forms are prepared 
by coating the tablets so that the rate of solubility is controlled or individual 
encapsulating microparticles of varying size sothat the rate of dissolution can be 
controlled. With the development of modern synthetic ion exchange resins, 
pharmaceutical industry adapted the ion exchange technology to achieve sustained 
release of drug. 
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1.1 Concept of Sustained Release (SR):           (Kranthi Kumar Kotta.et al..2010) 
The object of sustain release of drugs, in a general way is to modify the normal 
behavior of the drug molecule in physiological environment. The following are the 
benefits of sustained release formulations. 
1. Sustained action at predetermined rate by maintaining a relatively constant, 
effective drug level in the body with minimum side effects 
2. Localization of drug action by special placement of a controlled release 
systems usually rate controlled adjacent to or in diseased tissue of organ. 
3. Targeting drug action by using or chemical derivatives to deliver drug to 
particular target cell type. 
1.1.1 Sustained release drug delivery system:        (Remington., 2002) 
Non immediate release drug delivery system may be conveniently divided into four 
categories. 
i. Delayed release 
ii. Sustained release 
a. Controlled release 
b. Prolonged release 
iii. Site specific release 
iv. Receptor release 
Sustained release system is a drug delivery that achieves release of drug over an 
extended period of time. If the system is successful at maintaining controlled drug 
level in the blood, it is considered as a controlled release system. If it is unsuccessful 
but extends the duration of action over that achieved by conventional delivery it is 
considered as a prolonged release system. 
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1.1.2 Advantages of Sustained Release Formulations     (Sharma Nk., 1998) 
1.  Overcome patient compliance problems. 
2.  Minimize or eliminate systemic side effects by reduced fluctuation in drug level. 
3.  Minimize drug accumulation with chronic dosing. 
4. Improve efficiency in treatment 
a) Cures or controls disease condition more promptly. 
b) Improves therapy and reduce the undesirable side effect by maintains the drug 
level in plasma for prolonged period of time. 
c) Improves bioavailability of some drugs. 
5. Economy i.e. reduction in health care costs. The average cost of treatment over an 
extended time period may be less. 
6. Reduce dose frequency 
7. Reduce fluctuations in blood levels 
1.1.3 Disadvantages of Sustained Release Formulations: 
1) Decreased systemic availability in comparison to immediate release conventional 
dosage forms, which may be due to incomplete release, increased first-pass 
metabolism, increased instability, insufficient residence time for complete 
release, site specific absorption, pH dependent stability etc. 
2) Poor in vitro – in vivo correlation. 
3) Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity 
reactions. 
4) Reduced potential for dose adjustment of drugs normally administered in varying 
strengths. 
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1.1.4 Classification of sustained release delivery system: 
1. Rate program drug development systems 
2.  Activated modulated drug development systems. 
3. Feed base modulated drug development systems. 
4. Site targeting drug development 
All categories consist of common structural features. 
i. Drug reservoir compartment 
ii. Rate controlling element            
iii. Energy source 
1.1.5 Attributes of drug candidates for sustained release systems: 
There are specific attributes that a drug must possess for being suitable for 
incorporation in sustained release systems. 
1. The drug must be effective in a relatively small dose or else the large dose 
required will make the preparation difficult to swallow. 
2. Drugs with very short biological half life (less than 2 hrs) such as levodopa, 
penicillin G, and furosemide require relatively large dose for incorporating in 
sustain Release systems. His renders the dosage form very difficult to swallow. 
3. Drugs with long biological half live (more than8 hrs) inherently or sustain release 
and thus are viewed as questionable candidates for sustained release formulations. 
4. Absorption of poorly water soluble drugs is often limited by dissolution rate. 
Incorporation of such drugs into sustained release formulations is therefore 
unnecessary and is likely to reduce the overall absorption efficiency. 
5. Very insoluble drugs whose availability is controlled by dissolution (example 
griseofulvin) may not benefit from this, since the amount of drug available for 
absorption is limited by the poorly solubility of the compound. 
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6. Drugs with narrow requirement for absorption (e.g. drugs dependent on position 
in the GI tract for optimum absorption) are also poor candidates for oral sustained 
release formulations, since absorption must occur throughout the length of the gut. 
E.g. vitamin C is absorbed preferentially from the upper portion of the intestine 
and therefore it’s sustain release formulation are of questionable therapeutic value. 
7. Before proceeding with the design of sustained release form of an appropriate 
drug, the formulated should have an understanding the pharmacokinetics of the 
candidate, should be that pharmacologic effect can be positively correlated with 
drug blood levels, and should be knowledgeable about the therapeutic dosage, 
including the minimum effective and maximum safe doses. 
Although the above characteristic are useful rules of thumb for deciding whether or 
not particular drug should be considered for sustained release drug delivery  system, 
there are several exceptions biological half life of nitroglycerin is less than 0.5hrs. it is 
rapidly metabolized in liver and is poorly absorbed orally. However, sustain release 
oral nitroglycerin obtained from these products provide adequate prophylaxis against 
anginal attacks but are inadequate to treat acute anginal episodes. 
1.2 Factors Influencing the Design and Performance of Sustained Release 
Products:                                                        (Bramhankar and Jaiswal, 1995) 
 The type of delivery system and route of administration of the drug presented 
in sustained drug delivery system may depend upon two properties They are 
 
 
I. Physicochemical Properties of drugs 
II. Biological Factors. 
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1.2.1 Physicochemical Properties of Drugs                    (Shalin A. Modi, et al..2011) 
1. Dose size: 
If an oral product has a dose size greater that 0.5gm it is a poor candidate for 
sustained release system, Since addition of sustaining dose and  possibly the 
sustaining mechanism will, in most cases generates a substantial volume product that 
unacceptably large. 
2. Ionization, PKa and Aqueous Solubility: 
The pH Partition hypothesis simply states that the unchanged form of a drug 
species will be preferentially absorbed through many body tissues. Therefore it is 
important to note the    relationship between thePKa of the compound and its 
absorptive environment. For many compounds, the site of maximum absorption will 
also be the area in which the drug is least soluble. 
3. Partition coefficient: 
 The compounds with a relatively high partition coefficient are 
predominantly lipid soluble and easily penetrate membranes resulting high 
bioavailability. Compounds with very low partition coefficient will have difficulty in 
penetrating membranes resulting poor bioavailability. Furthermore partitioning effects 
apply equally to diffusion through polymer membranes. 
4.Drug Stability:                    (Asija Rajesh, et al.. 2012, Shalin A. Modi, et al..2011) 
In general the drugs, which are unstable in GIT environment poor candidates for 
oral sustained release forms. Orally administered drugs can be subject to both acid 
base hydrolysis and enzymatic degradation. Degradation will proceed at the reduced 
rate for drugs in the solid state, for drugs that are unstable in stomach; systems that 
prolong delivery ever the entire course of transit in GI tract are beneficial. 
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Compounds that are unstable in the small intestine may demonstrate decreased 
bioavailability when administered form a sustaining dosage from. This is because 
more drug is delivered in small intestine and hence subject to degradation. 
5. Protein Binding: 
 It is well known that many drugs bind to plasma proteins with a concomitant 
influence on the duration of drug action. Since blood proteins are mostly recalculated 
and not eliminated. Drug protein binding can serve as depot for drug producing a 
prolonged release profile, especially if a high degree of drug binding occurs. 
Extensive binding to plasma proteins will be evidenced by a long half life of 
elimination for drugs and such drugs generally do not require a sustained release 
dosage form. 
6. Molecular size and diffusivity: 
The ability of drug to diffuse through membranes it’s so called diffusivity & 
diffusion coefficient is function of molecular size (or molecular weight).Generally, 
values of diffusion coefficient for intermediate molecular weight drugs, through 
flexible polymer range from 10-8 to 10-9 cm2/sec. with values on the order of 10-8 
being most common for drugs with molecular weight greater than 500, the diffusion 
coefficient  in many polymers frequently are so small that they are difficult to 
quantify i.e. less than 16-12 cm2/sec. Thus high molecular weight drugs and/or 
polymeric drugs should be expected to display very slow release kinetics in sustained 
release device using diffusion through polymer membrane. 
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1.2.2 II. Biological Factors (Shalin A. Modi, et al..2011) 
 1. Biological Half-Life: 
 Therapeutic compounds with half-life less than 8 hrs are excellent 
candidates for sustained release preparations. Drugs with very short half-life (less than 
2 hrs) will require excessively large amounts of drug in each dosage unit to maintain 
controlled effects. Compounds with relatively long half-lives, generally greater than 8 
hrs are not used in the sustained release dosage forms, since their effect is already 
sustained and also GI transit time is 8-12 hrs (Jantzenet al.. 1996). So the drugs, which 
have long -half life and short half- life, are poor candidates for sustained release 
dosage forms. 
4. Absorption: 
 The characteristics of absorption of a drug can greatly affect its 
suitability as a sustained release product. Drugs which are absorbed by specialized 
transport process (carrier mediated) and drug absorption at special sites of the 
gastrointestinal tract (Absorption Window) are poor candidates for sustained release 
products. 
5. Distribution: 
The distribution of drugs into tissues can be important factor in the overall drug 
elimination kinetics. Since it not only lowers the concentration of circulating drug but 
it also can be rate limiting in its equilibrium with blood and extra vascular tissue, 
consequently apparent volume  of distribution assumes different values depending on 
time course of drug disposition. For design of sustained/controlled release products, 
one must have information of disposition of drug. 
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6. Metabolism: 
 There are two factors associated with the metabolism of some drugs; 
however that present problems of their use in sustained-release systems. One is the 
ability of the drug to induce or inhibit enzyme synthesis; this may result in a 
fluctuating drug blood level with chronic dosing. The other is a fluctuating drug 
blood level due to intestinal (or other tissue) metabolism or through a hepatic first-
pass effect. 
Drugs that are significantly metabolized especially in the region of the small intestine 
can show decreased bioavailability from slower releasing dosage forms. The drugs 
should not have intestinal first pass effect and should not induce (or) inhibit 
metabolism are good candidates for sustained release dosage forms. 
1.3 Sustained (zero-order) drug release has been attempted to be achieved with 
various classes of sustained drug delivery system            (Caugh Isha, et al.. 2012) 
1. Diffusion sustained system. 
i) Reservoir type. 
ii) Matrix type 
2. Dissolution sustained system. 
i) Reservoir type. 
ii) Matrix type 
3. Methods using Ion-exchange. 
4. Methods using osmotic pressure. 
5. pH independent formulations. 
6. Altered density formulations. 
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1.3.1. Diffusion Sustained System                                             (Brahmankar., 2005) 
Basically diffusion process shows the movement of drug molecules from a region of a 
higher concentration to one of lower concentration. The flux of the drug J (in amount / 
area - time), across a membrane in the direction of decreasing concentration is given 
by Fick’s law. 
J= - D dc/dx. 
D = diffusion coefficient in area/ time 
dc/dx = change of concentration 'c' with distance 'x' 
In common form, when a water insoluble membrane encloses a core of drug, it must 
diffuse through the membrane. 
The drug release rate dm/ dt is given by 
dm/ dt= ADKΔ C/L 
Where, 
A  = Area. 
K  = Partition coefficient of drug between the membrane and     drug 
core. 
L = Diffusion path length (i.e. thickness of coat). 
ΔC = Concentration difference across the membrane. 
i) Reservoir Type                                                            (Khachane K.N, et al.. 2011) 
In the system, a water insoluble polymeric material encases a core of drug 
(Figure 1.1). Drug will partition into the membrane and exchange with the fluid 
surrounding the particle or tablet. Additional drug will enter the polymer, diffuse to 
the periphery and exchange with the surrounding media. 
 
5-FLUOROURACIL MICROCAPSULES                                     INTRODUCTION 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY,MELMARVATHUR. Page 11 
 
 
Fig 1.1: Schematic representation of diffusion sustained drug release: Reservoir 
system 
 
ii) Matrix Type                                                               (Caugh Isha, et al.. 2012) 
A solid drug is dispersed in an insoluble matrix and the rate of release of drug 
is dependent on the rate of drug diffusion and not on the rate of solid dissolution. 
Higuchi has derived the appropriate equation for drug release for this system: 
Q = Dε/ T [2 A –εCs] Cst½ 
Where; 
Q  = Weight in gms of drug released per unit area of surface       at time 
t. 
D  = Diffusion coefficient of drug in the release medium. 
ε  = Porosity of the matrix. 
Cs  = Solubility of drug in release medium. 
T = Tortuosity of the matrix. 
A  = Concentration of drug in the tablet, as gm/ ml. 
The release rate can be given by following equation 
Release rate = AD / L = [C1- C2] 
Where; 
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 A = Area. 
 D  = Diffusion coefficient. 
 C1 = Drug concentration in the core. 
 C2  = Drug concentration in the surrounding medium. 
 L = Diffusional path length. 
Thus diffusion sustained products are based on two approaches the first approach 
entails placement of the drug in an insoluble matrix of some sort. The eluting medium 
penetrates the matrix and drug diffuses out of the matrix to the surrounding pool for 
ultimate absorption. The second approach involves enclosing the drug particle with a 
polymer coat. In this case the portion of the drug which has dissolved in the polymer 
coat diffuses through an unstirred film of liquid into the surrounding fluid. 
1.3.2 Dissolution Sustained Systems (Caugh Isha, et al.. 2012) 
A drug with a slow dissolution rate is inherently sustained and for those drugs 
with high water solubility, one can decrease dissolution through appropriate salt or 
derivative formation. These systems are most commonly employed in stomach from 
the effects of drugs such as Aspirin; a coating that dissolves in natural or alkaline 
media is used. This inhibits release of drug from the device until it reaches the higher 
pH of the intestine. In most cases, enteric coated dosage forms are not truly sustaining 
in nature, but serve as a useful function in directing release of the drug to a special 
site. The same approach can be employed for compounds that are degraded by the 
harsh conditions found in the gastric region. 
i) Reservoir Type 
Drug is coated with a given thickness coating, which is slowly dissolved in the 
contents of gastrointestinal tract. If the outer layer is quickly releasing bolus dose of 
the drug, initial levels of the drug in the body can be quickly established with pulsed 
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intervals. Although this is not a true sustained release system, the biological effects 
can be similar. An alternative method is to administer the drug as group of beads that 
have coating of different thickness. Since the beads have different coating thickness, 
their release occurs in a progressive manner. Those with the thinnest layers will 
provide the initial dose. The maintenance of drug levels at late times will be achieved 
from those with thicker coating. This is the principle of the spansule capsule. 
Cellulose nitrate phthalate was synthesized and used as an enteric coating agent for 
acetyl salicylic acid tablets. 
ii) Matrix Type 
The more common type of dissolution sustained dosage form as shown in fig 
1.2. It can be either a drug impregnated sphere or a drug impregnated tablet, which 
will be subjected to slow erosion. 
 
Fig 1.2: Schematic representation of diffusion sustained drug release: matrix system 
Two types of dissolution sustained pulsed delivery systems 
(Caugh Isha, et al.. 2012) 
 Single bead type device with alternating drug and rate controlling layer. 
 Beads containing drug with differing thickness of dissolving coats. Amongst 
sustained release formulations, hydrophilic matrix technology is the most 
widely used drug delivery system due to following advantages: 
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 Provide desired release profiles for a wide therapeutic drug category, dose and 
solubility. 
  Simple and cost effective manufacturing using existing tableting unit 
operation equipment. 
 Robust formulation. 
 Broad regulatory and patient acceptance. 
 Ease of drug release modulation through level and choice of polymeric 
systems and function coatings. 
1.3.3. Methods using Ion Exchange 
It is based on the formation of drug resin complex formed when a ionic 
solution is kept in contact with ionic resins. The drug from these complexes gets 
exchanged in gastrointestinal tract and released with excess of Na+ and Cl- present in 
gastrointestinal tract. 
Anion Exchangers: Resin+ - Drug - + Cl- goes to Resin+ Cl- + Drug- 
Cation Exchangers: Resin- - Drug+ + Na+ goes to Resin- Na+ + Drug+ 
These systems generally utilize resin compounds of water insoluble cross linked 
polymer. They contain salt forming functional group in repeating positions on the 
polymer chain. The release rate can be sustained by coating the drug resin complex by 
microencapsulation process. 
1.3.4. Methods Using Osmotic Pressure (Caugh Isha, et al.. 2012) 
A semi permeable membrane is placed around a tablet, particle or drug 
solution that allows transport of water into the tablet with eventual pumping of drug 
solution out of the tablet through a small delivery aperture in tablet coating. 
Two types of osmotically sustained systems are 
 Type A contains an osmotic core with drug. 
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 Type B contains the drug in flexible bag with osmotic core surrounding. 
1.3.5. pH– Independent Formulations 
The gastrointestinal tract present some unusual features for the oral route of 
drug administration with relatively brief transit time through the gastrointestinal tract, 
which constraint the length of prolongation, further the chemical environment 
throughout the length of gastrointestinal tract is constraint on dosage form design. 
Since most drugs are either weak acids or weak bases, the release from sustained 
release formulations is pH dependent. However, buffers such as salts of amino acids, 
citric acid, phthalic acid phosphoric acid or tartaric acid can be added to the 
formulation, to help to maintain a constant pH thereby rendering pH independent drug 
release. A buffered sustained release formulation is prepared by mixing a basic or 
acidic drug with one or more buffering agent, granulating with appropriate 
pharmaceutical excipients and coating with gastrointestinal fluid permeable film 
forming polymer. When gastrointestinal fluid permeates through the membrane, the 
buffering agents adjust the fluid inside to suitable constant pH thereby rendering a 
constant rate of drug release e.g. propoxyphene in a buffered sustained release 
formulation, which significantly increase reproducibility. 
1.3.6. Altered Density Formulations              (Caugh Isha, et al.. 2012) 
It is reasonable to expect that unless a delivery system remains in the vicinity 
of the absorption site until most; if not all of it would have limited utility. To this end, 
several approaches have been developed to prolong the residence time of drug 
delivery system in the gastrointestinal tract. 
High Density Approach 
In this approach the density of the capsules must exceed that of normal 
stomach content and should therefore be at least 1-4gm/cm3. 
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Low Density Approach 
Globular shells which have an apparent density lower than that of gastric fluid 
can be used as a carrier of drug for sustained release purpose. 
1.4Rationale for the selection of Microparticles: 
Most of the research effort in developing novel drug delivery systems has been 
focused on oral controlled release dosage forms. Among them, in the last decade, 
multiple unit dosage forms, such as beads or micro particles. Have gained in 
popularity for different reasons when compared to non-disintegrating single-unit 
dosage forms. They distribute more uniformly in the gastrointestinal tract, resulting in 
more uniform and reduce local irritation, and also avoid the unwanted intestinal 
retention. 
1.4.1 Micro particles: 
These are particles with size more than ‘1’ µm, containing the polymer. At 
present, there is no universally accepted size range that particles must have in order to 
be classified as micro particles. However, may workers classify the particles smaller 
than ‘1’ µm, as nanoparticles as and those more than 1000 µm, as macro particles. 
Classification: Micro particles are classified into two groups. 
Micro particles 
 
 
 
    Microcapsules                                                                        Microspheres 
(Micrometric Reservoir System)                        (Micrometric Matrix System) 
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1.4.2 Microcapsules:                                                  (Nitika Agnihotri, et al..2012) 
Microcapsules are small particles that contain an active agent or core material 
surrounded by a coating or shell. (Commercial microcapsules typically have a 
diameter between 3 & 800 micrometer and 10-90% core). 
1.4.3 Microspheres: 
Microspheres are solid, spherical particles containing dispersed drug 
molecules, either in solution or crystalline form, among the polymer molecule. 
 
Fig 1.3: Microsphere & microcapsule 
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1.4.4 TYPES OF MICROCAPSULES: 
 
Microcapsules have an either spherical geometry with a continuous core region 
surrounded by a continuous shell or have an irregular geometry and contain a number 
of small droplets or particles of core. 
 
Reasons for Encapsulation: 
There are several reasons why substances may be encapsulated 
1. To protect reactive substances from the environment 
2. To convert liquid active components into a dry solid system 
3. To separate incompatible components for functional reasons 
4. To mask undesired properties of the active components 
5. To protect the immediate environment of the microcapsules from the active 
components 
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6. To control release of the active components for delayed (timed) release or long-
acting (sustained) release 
1.5 CRITERIA FOR COATING MATERIALS: 
The coating materials should meet the following ideal criteria:- 
1. Capable of forming a film that is cohesive with the core material. 
2. Chemically compatible and non-reactive with the core material. 
3. Provide the desired coating properties such as strength, flexibility, 
impermiability, optical properties and stability. 
The selection of a given coating material often can be aided by the review of existing 
literature and by the study of free or cast films. 
1.6 Release mechanisms .                            ( Christopher S. Brazel, et al.. 2010) 
Mechanisms of drug release from microcapsules are 
1. Degradation controlled monolithic system: 
The drug is dissolved in matrix and is distributed uniformly throughout. The drug 
is strongly attached to the matrix and is released on degradation of the matrix. The 
diffusion of the drug is slow as compared with degradation of the matrix. 
2. Diffusion controlled monolithic system 
Here the active agent is released by diffusion prior to or concurrent with the 
degradation of the polymer matrix. Rate of release also depend upon where the 
polymer degrades by homogeneous or heterogeneous mechanism. 
3. Diffusion controlled reservoir system 
Here the active agent is encapsulated by a rate controlling membrane through 
which the agent diffuses and the membrane erodes only after its delivery is 
completed. In this case, drug release is unaffected by the degradation of the matrix. 
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4. Erosion 
Erosion of the coat due to pH and enzymatic hydrolysis causes drug release 
with certain coat material like glyceryl mono stearate, beeswax and steryl alcohol etc.  
 
1.7 METHOD OF MICROCAPSULE PREPARATION: 
(1) Coacervation – phase separation  
(2) Interfacial polymerization   
(3) In-Situ polymerization     
(4) Solvent evaporation    
(5) Solvent extraction 
(6) Spray drying 
(7) Fluidized Bed Coating 
(8) MultiorificeCentrifugal process 
(9) Pan coating 
 
1. Coacervation – Phase Separation :                      (Nitika Agnihotri, et al.. 2012) 
Coacervation is a colloid phenomenon. If one starts with a solution of a colloid 
in an appropriate solvent, then according to the nature of the colloid, various changes 
can bring about a reduction of the solubility of the colloid. As a result of this 
reduction a large part of the colloid can be separated out into a new phase. The 
original one phase system becomes two phases. One is rich and the other is poor in 
colloid concentration. The colloid-rich phase in a dispersed state appears as 
amorphous liquid droplets called coacervate droplets. Upon standing these coalesce 
into one clear homogenous colloid-rich liquid layer, known as the coacervate layer 
which can be deposited so as to produce the wall material of the resultant capsules. 
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Coacervation may be initiated in a number of different ways. As the coacervate forms, 
it must wet the suspended core particles or core droplets and coalesce into a 
continuous coating for the process of microencapsulation to occur. The final step for 
microencapsulation is the hardening of the coacervate wall and the isolation of the 
microcapsules, usually the most difficult step in the total process. 
This process of microencapsulation is generally referred to The National Cash 
Register (NCR) Corporation and the patents of B.K. Green.  
This process consists of three Steps- 
• Formation of three immiscible phases; a liquid manufacturing phase, a core 
material phase and a coating material phase 
• Deposition of the liquid polymer coating on the core material 
• Rigidizing of the coating material 
 
Step-1: The first step of coacervation phase separation involves the formation of three 
immiscible chemical phases: a liquid vehicle phase, a coating material phase and a 
core material phase. The three phases are formed by dispersing the core material in a 
solution of coating polymer, the vehicle phase is used as a solvent for polymer. The 
coating material phase consists of a polymer in a liquid phase, is formed by using one 
of the of phase separation- coacervation method, i.e. .by changing the temperature of 
the polymer solution, by adding a solution, or by inducing a polymer- polymer 
interaction. 
Step-2: It involves the deposition of the liquid polymer coating upon the core 
material. This is done by controlled mixing of liquid coating material and the core 
material in the manufacturing vehicle.  
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Step-3: In the last step rigidizing of the coating material done by the thermal, cross 
linkingdesolvationtechniques.
 
Fig 1.4: Coacervation process: (a) Core material dispersion in solution of shell 
polymer; (b) Separation of coacervate from solution; (c) Coating of core material by 
micro droplets of coacervate; (d) Coalescence of coacervate to form continuous shell 
around core particles. 
Simple coacervation 
Simple coacervation involves the use of either a second more-water soluble 
polymer or an aqueous non-solvent for the gelatin. This produces the partial 
dehydration/desolvation of the gelatin molecules at a temperature above the gelling 
point. This results in the separation of a liquid gelatin-rich phase in association with 
an equilibrium liquid (gelatin-poor) which under optimum separation conditions can 
be almost completely devoid of gelatin. Simple coacervation can be effected either by 
mixing two colloidal dispersions, one having a high affinity for water, or it can be 
induced by adding a strongly hydrophilic substance such as alcohol or sodium sulfate 
[14].
 The water soluble polymer is concentrated in water by the action of a water 
miscible, non-solvent for the emerging polymer (gelatin) phase. Ethanol, acetone, 
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dioxane, isopropanol and propanol have been used to cause separation of coacervate 
of gelatin, polyvinyl alcohol and methyl cellulose. Phase separation can be effected by 
the addition of an electrolyte such as an inorganic salt to an aqueous solution of a 
polymer such as gelatin, polyvinyl alcohol or carboxymethyl cellulose. A typical 
simple coacervation using gelatin colloid is as follows: to a 10 percent dispersion of 
gelatin in water, the core material is added with continuous stirring and at a 
temperature of 40°C. Then a 20 percent sodium sulfate solution or ethanol is added at 
50 to 60 percent by final total volume, in order to induce the coacervation. This 
system is cooled to 50°C; then, it is necessary to insolubilize the coacervate capsules 
suspended in the equilibrium liquid by the addition of a hardening agent such as 
glutaraldehyde and adjusting the pH. The resulting microcapsules are washed, dried 
and collected  
 
2. Interfacial Polymerization (Ift): 
In this method the capsule shell is formed at or on the surface of a droplet or 
particle by polymerization of reactive monomers. 
If the microencapsulating core is water-immiscible liquid then a multifunctional 
monomer is dissolved in the core material. This solution is dispersed in an aqueous 
phase containing dispersing agent. A co-reactant is then added to the aqueous phase. 
This produces a rapid polymerization reaction at the interface which generates the 
capsule shell. 
Advantage: It is a versatile technology able to encapsulation a wide range of core 
materials, including aqueous solutions, water immiscible liquids and solids. 
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Disadvantage: 
1. Because one of the reactants used to create the capsule shell is dissolved in the 
core material and is free to react with any groups located on core material 
molecules to create new molecules. 
2. Capsule shell is not uniformly deposited around the core. 
3. In situ polymerization: 
In a few microencapsulation processes, the direct polymerization of a single 
monomer is carried out on the particle surface. In one process, E.g. Cellulose fibers 
are encapsulated in polyethylene while immersed in dry toluene. Usual deposition 
rates are about 0.5μm/min. Coating thickness ranges 0.2-75μm. The coating is 
uniform, even over sharp projections [27]. 
4. Solvent-Evaporation Method :                            (Hammad Umar, et al.. 2011) 
(Emulsification- Evaporation Method) 
This technique is based on the evaporation of the internal phase of an 
emulsion by agitation. Initially, the coating polymeric material is dissolved in a 
volatile organic solvent. The core to be encapsulated is then dispersed in the coating 
polymer solution to form a suspension or emulsion. 
In the next step, this organic solution is emulsified under agitation in dispersing 
phase, which is immiscible with the organic solvent, which contains the emulsifier. 
Once the emulsion is stabilized, agitation is maintained and the solvent evaporates 
after diffusing through the continuous phase. This results in the formation of 
microcapsule. On the completion of the process, the microcapsules held in suspension 
in the continuous phase are recovered by filtration or centrifugation and are washed 
and dried. 
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Core material dispersed (aqueous)      Dispersing 
Inorganic solution of coating polymer    media with Emulsifier 
 
 
Formulation of emulsion under mechanical stirring 
Evaporation of Organic     Formation of Solid 
Solvent    Microcapsules 
 
Solvent evaporation technique is basically divided into 3 different types of 
techniques 
(I) Oil in water emulsion. 
(II)Multiple emulsions: w/o/w: 
Advantage: This process is more effective when the water solubility of the drug is 
high and partitioning between the organic phases is disfavourable. 
Application: This process is used for encapsulation of the drugs with weak dose and 
which are strongly water soluble. 
Mechanism of solvent evaporation method: 
 This system is characterized by the existence of several interfaces through 
which mass transfer occurs during particle formation, as shown in the below figure: 
 
Fig 1.5: Mechanism of solvent evaporation method 
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Organic solvent of the dispersed phase of the emulsion is eliminated in two stages: 
1. Diffusion of the solvent in the dispersing phase. 
2. Elimination of the solvent at dispersing phase – air interface. 
The formation of solid microcapsule is brought about by the evaporation of the 
volatile solvent L1 at interface L2/G. During the course of solvent evaporation, a 
partitioning is produced across the interface L1/L2 from the dispersed phase to 
continuous phase leading to the formation of solid microcapsules. 
 
5. Solvent – Extraction method: 
 As mentioned in the previous method, the organic solvent of the dispersed 
phase of the emulsion is eliminated in two stages i.e. 
i. Diffusion into continuous phase & 
ii. Elimination of solvent at continuous phase – air interface. 
If one uses a continuous phase which will immediately extract the solvent of the 
dispersed phase, the evaporation stage is no longer necessary in microencapsulation. 
In practice it is achieved 
a. By using large volume of dispersing phase w.t.o dispersed phase. 
b. By choosing a co-solvents in dispersed phase, of which at least one has a great 
affinity for the dispersing phase. 
c. By formulating a dispersing phase with two solvents in which one acts as a 
solvent extractor of the dispersed phase. 
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6. Spray–drying                                      (Nitika Agnihotri, et al.. 2012) 
Spray drying serves as a microencapsulation technique when an active 
material is dissolved or suspended in a melt or polymer solution and becomes trapped 
in the dried particle. Coating solidification in the case of spray drying is effected by 
rapid evaporation of a solvent in which the coating material is dissolved. Coating 
solidification in spray congealing methods, however, is accomplished by thermally 
congealing a molten coating material or by solidifying a dissolved coating by 
introducing the coating - core material mixture into a nonsolvent. Removal of the 
nonsolvent or solvent from the coated product is then accomplished by sorption, 
extraction, or evaporation techniques. In practice, microencapsulation by spray drying 
is conducted by dispersing a core material in a coating solution, in which the coating 
substance is dissolved and in which the core material is insoluble, and then by 
atomizing the mixture into air stream. The air, usually heated, supplies the latent heat 
of vaporization required to remove the solvent from the coating material, thus forming 
the microencapsulated product21. The equipment components of a standard spray 
dryer include an air heater, atomizer, main spray chamber, blower or fan, cyclone and 
product collector. Microencapsulation by spray congealing can be accomplished with 
spray drying equipment when the protective coating is applied as a melt. Coating 
solidification (and microencapsulation) is accomplished by spraying the hot mixture 
into a cool air stream. Waxes, fatty acids and alcohols, polymers and sugars, which 
are solids at room temperature but meltable at reasonable temperatures, are applicable 
to spray congealing techniques. Typically, the particle size of spray congealed 
products can be accurately controlled when spray drying equipment is used, and has 
been found to be a function of the feed rate, the atomizing wheel velocity, dispersion 
of feed material viscosity, and variables 24. 
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Advantage: Low cost of encapsulation and able to produce large amount of 
microcapsules. 
Disadvantage: This process is limited to coating material soluble in water, but the list 
of water soluble coating materials are limited. 
 
 
Fig. 1.6: Spray Dryer 
7. Fluidized bed coating (Wurster Air Suspension): 
It consists of the dispersing of solid core material in a supporting air steam and 
then spray coating of the air suspended particles. 
Advantage: Able to handle an extremely wide range of coating formulations. 
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8. Multi-orifice – Centrifugal processes: 
In this process it utilizes centrifugal forces to hurl a core material particle 
through an enveloping microencapsulating membrane, there by effecting mechanical 
microencapsulation. 
9. Pan coating                                                 (Nitika Agnihotri, et al.. 2012) 
In this pan coating the particles are tumbled in a pan or other device while the 
coating material is applied slowly17. 
The particles are tumbled in a pan or other device while the coating material is 
applied slowly with respect to microencapsulation, solid particles greater than 600 
microns in size are generally considered essential for effective coating, and the 
process has been extensively employed for the preparation of controlled-release 
beads. Medicaments are usually coated onto various spherical substrates such as 
nonpareil sugar seeds, and then coated with protective layers of various polymers. 
 
Fig 1.7: Representation of a typical pan coating 
Usually, to remove the coating solvent, warm air is passed over the coated materials 
as the coatings are being applied in the coating pans. In some cases, final solvent 
removal is accomplished in a drying oven. 
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Strategy for improving Encapsulation efficiency of drug: 
i. Water solubility of the drug can be reduced by chemical modification prior to 
its incorporation in the organic phase. However, such structural 
modification may give rise to toxicological problems. 
ii. Modifying the dispersing phase of the emulsion to reduce leakage of the drug 
from the oily droplets of polymer solution. Modifications like, 
a. Saturating the continuous phase with the drug. 
b. Adjusting the pH of this same phase 
c. Adding the electrolytes. 
1.8 POLYMERS USED FOR MICROENCAPSULATION: 
(Hammad Umar, et al..2011) 
(I)  Water soluble resins 
(1) Gelatin 
(2) Gum Arabia 
(3) Starch 
(4) Polyvinyl pyrrolidone 
(5) Sodium carboxy methyl cellulose 
(6) Hydroxy ethyl cellulose 
(7) Mehtyl cellulose 
(8) Arabinogalactam 
(9) Polyvinyl alcohol 
(10) Polyacrylic acid 
(II)  Water insoluble resins 
(1)    Ethyl cellulose 
(2) Polmethyl methacrylate (PMMA) 
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(3) Polymethacrylate (Eudragit) 
(4)    Polyethylene 
(5)    Polyamide (Nylon) 
(6)    Poly (Ethylene-Vinyl acetate) 
(7)    Cellulose nitrate 
(8)    Silicones 
(9)    Poly (lactide-co-glycolide) 
(10) Cellulose acetate butyrate 
(III) Waxes & Lipids 
1. Paraffin 
2. Carnauba Wax 
3. Spermaceti 
4. Bees wax 
5. Stearic acid 
6. Strearyl alcohol 
7. Glyceryl stearates 
(IV) Enteric Resins 
1. Shellac 
2. Cellulose acetate phthalate  
3. Zein 
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1.9 Application of microencapsulation.                    (Nitika Agnihotri, et al.. 2012) 
There are many reasons why drugs and related chemicals have been 
microencapsulated. The technology has been used widely in the design of controlled 
release and sustained release dosage forms. 
 
Fig.1. 8: Applications of microencapsulation. 
• To mask the bitter taste of drugs like Paracetamol, Nitrofurantoin etc. 
• Many drugs have been microencapsulated to reduce gastric and other G.I. tract 
irritations. Sustained release Aspirin preparations have been reported to cause 
significantly less G.I. bleeding than conventional preparations. 
• A liquid can be converted to a pseudo-solid for easy handling and storage.  
e.g. Eprazinone. 
• Hygroscopic properties of core materials may be reduced by 
microencapsulation e.g. Sodium chloride. 
• Carbon tetra chlorides and a number of other substances have been 
microencapsulated to reduce their odor and volatility. 
• Microencapsulation has been employed to provide protection to the core 
materials against atmospheric effects, e.g. vitamin A. 
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• Separation of incompatible substance has been achieved by encapsulation. 
• Cell immobilization: In plant cell cultures, Human tissue is turned into bio-
artificial organs, in continuous fermentation processes. 
• Protection of molecules from other compounds. 
• Drug delivery: Controlled release delivery systems. 
• Quality and safety in food, agricultural & environmental sectors. 
• Beverage production, Soil inoculation. 
• In textiles: means of imparting finishes. 
• Protection of liquid crystals. 
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2. AIM AND OBJECTIVES 
 
Cancer is a leading cause of death world wide. More than 70% of all cancer 
deaths occurred in low and middle-income countries. Deaths from cancer world wide 
are projected to continue rising, with an estimated 12 million deaths in 2030. 
Treatment of cancer includes chemotherapy, radiation therapy, gene therapy, 
photodynamic therapy, biologic therapy, surgical removal of tumor cells, etc. Cancer 
treatments vary according to the type of cancer and the extent of the tumor. 
Chemotherapy is the most convenient and non-expensive when compared to other 
modes of treatment. Varieties of anticancer drugs are available in the market and 
some of them are under clinical trials. The main problem with anti-cancer drugs is 
that they not only affect the cancerous cells but also affect the normalcells. These 
happen dueto non-specific targeting to cancerous cells and hence other normal cells 
get affected. 
Recently, drug targeting especially targeting of drugs by microcapsules have 
been getting much attention by the researchers for treating cancer. Acritical advantage 
in treating cancer with microcapsules is the inherent leaky vasculature present serving 
cancerous tissues. The effective vascular architecture, created dueto rapid 
vascularization necessary to serve fast-growing cancers, coupled with poor lymphatic 
drainage allows an enhanced permeation and retention effect. 
Targeting the tumor vasculature is a strategy that can allow targeted delivery 
to a wide range of tumor types. Tremendous opportunities exist for using 
microcapsulesas sustained drug delivery systems for cancer treatment. Natural and 
synthetic co-polymers including albumin, fibrinogen, alginate, chitosan and collagen 
have been used forther fabrication of microcapsules. 
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Objectives: 
 The objective ofthe present study is preparing the microcapsules of                
5-fluorouraccil in order to provide sustained release. The micro capsules of                    
5-fluorouracil were formulated by coacervation phase separation by change in pH 
method and emulsion solvent evaporation.The micro capsules is evaluated with 
respect to particle size, drug content, entrapment efficiency. Drug polymer 
compatibility studied by FTIR and DSC. In-vitro drug release study, release kinetics 
studies and stability studies. 
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3. PLAN OF WORK 
 
 Literature survey.  
 Materials and equipments. 
 Preformulation studies. 
 Characterization of Drug. 
 Appearance. 
 Melting Point Determination. 
 Solubility Study. 
 UV Spectroscopy (λmax). 
 IR Spectroscopy. 
 Loss on drying. 
 Drug – Polymers InteractionStudies. 
 Fourier transforms Infra-Red (FTIR) Spectroscopy Study. 
 Differential Scanning Calorimetry (DSC) Analysis. 
 Preparation of 5-fluorouracil microcapsules. 
 Evaluation of 5-fluorouracil microcapsules. 
 Appearance. 
 Particle size. 
 Evaluation of micrcapsules. 
 Content uniformity. 
 Scanning electron microscopy. 
 Invitro drug release studies. 
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 Release drug data model fitting. 
 Results and Discussion. 
 Summary and Conclusion. 
 Future Prospects. 
 Bibliography. 
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4. LITERATURE SURVEY 
 
2.1. Literature Review: 
Alaa Eldeen Bakry Yassin., et al. (2010)  The aim of this study was to formulate a 
new orally-administered colon delivery system of 5-flurouracil (5-FU) for the 
treatment of colon cancer. The system was designed to target 5-FU directly to the 
colon with high potential of much more effective and less toxic colon cancer 
treatment. The system was prepared by compression coating technique using 
granulated chitosan. The method was optimized by studying the effect of granulation 
and thickness of the coat with respect to the in vitro performance in a medium 
mimicking mouth-to-colon environment. The in vivo selectivity of the system was 
assessed by X-ray imag- ing technique using beagle dogs. Results showed that 
granulation of chitosan were effective in protecting against the known acid solubility 
of the polymer. Formula (F7) with coat weight of  50 mg/tablet exhibited the best 
protection profile with <10% of the drug released after 6 h. The resistance of the 
system to the simulated gastro-intestinal media was reduced as the chitosan coat 
weight decreases. The performance of the system in a rat caecal contents containing-
medium showed that the susceptibility of this system for the enzymatic degradation 
by colonic enzymes. The X-ray imaging gave rise to the in vivo selectivity of this 
system for colon targeting by showing the resistivity of the system to the stomach and 
small intestine environment and the selective disintegration of the system inside the 
largebowl. 
A.V Yadav., et al.. (2009) Aceclofenac was formulated as novel enteric 
microcapsules for improved delivery to the intestine using thepolymer ethyl cellulose 
as the retardant material. Micro encapsulation of Aceclofenac was done to achieve a 
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controlled drugrelease profile suitable for per oral administration. Aceclofenac was 
used as core and microcapsules were prepared by anemulsion solvent evaporation 
method. The prepared microcapsules were evaluated for size analysis, drug 
content,encapsulation efficiency, wall thickness, optical microscopy and drug release 
characteristics. All microcapsules obtained werediscrete, large sized, free flowing and 
spherical in shape. Aceclofenac release from microcapsules followed higuchi model 
andinfluenced by the size of the microcapsules. Slow release of Aceclofenac from 
ethyl cellulose microcapsules over 12 hour’s was observed. 
Krishnaiah YS, Satyanarayana V., et al. (2012) 
Intravenous administration of 5-fluorouracil for colon cancer therapy produces severe 
systemic side-effects due to its cytotoxic effect on normal cells. The broad objective 
of the present study was to develop novel tablet formulations for site-specific delivery 
of 5-fluorouracil to the colon without the drug being released in the stomach or small 
intestine using guar gum as a carrier. Fast-disintegrating 5-fluorouracil core tablets 
were compression coated with 60% (FHV-60), 70% (FHV-70) and 80% (FHV-80) of 
guar gum, and were subjected to in vitro drug release studies. The amount of 5-
fluorouracil released from the compression-coated tablets in the dissolution medium 
at different time intervals was estimated by a HPLC method. Guar gum compression-
coated tablets released only 2.5-4% of the 5-fluorouracil in simulated GI fluids. When 
the dissolution study was continued in simulated colonic fluids (4% w/v rat caecal 
content medium) the compression-coated FHV-60, FHV-70 and FHV-80 tablets 
released another 70, 55 and 41% of the 5-fluorouracil respectively. The results of the 
study show that compression-coated tablets containing 80% (FHV-80) of guar gum 
are most likely to provide targeting of 5-fluorouracil for local action in the colon, 
since they released only 2.38% of the drug in the physiological environment of the 
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stomach and small intestine. The FHV-80 formulation showed no change either in 
physical appearance, drug content or dissolution pattern after storage at 40 degrees 
C/RH 75% for 6 months. The differential scanning calorimetric study showed that 5-
fluorouracil did not interact with the formulation excipients used in the study. 
Shaik. Shabbeer., et al. (2010)   
The present work describes the preparation of Sodium alginate/chitosan 
microcapsules containing 5-Fluorouracil (5-FU) intended for colon-specific delivery. 
The alginate/chitosan micro granules were prepared by the cross linking technique 
with calcium chloride(4%). Microscopy and Digital photography was used for 
morphology observation, which shows spherical shape but rough surface of the micro 
particles. Transmission infrared spectra of chitosan powder, 5-fluorouracil, sodium 
alginate pectin, and prepared microcapsules were acquired to draw information on the 
molecular state of chitosan and 5-fluorouracil. Differential scanning calorimetry 
(DSC) studies of 5-Fluorouracil, Chitosan, sodium alginate and pectin, were 
performed with PerkinElmer Thermal Analysis (Mettler Toledo 821Thermal analyzer) 
Calibrated with indium as standard. For thermogram acquisition The drug content and 
release profile of 5-FU was determined by UV–Vis absorption measurement at λ max 
266 nm. The drug content was found to be 0.061mg of 5-FU /mg of alginate/chitosan 
microcapsules. The swelling behavior and release of drug was determined at two 
different pH conditions i.e. at pH 1.2 and pH 6.8. micro particles were swelling but 
did not dissolves give more sustain manner of release. In order to study the effect of 
alginate on drug release from microcapsules. Accordingly, three different batches  
(F1, F2 & F3) containing 1.5% w/v, 2.0% and 2.5% w/v of alginate based  
microcapsules were prepared (batches A1,A2 and A3). The results of in vitro studies 
shown 5-fluorouracil remain intact and shows minimal drug release in stomach and 
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small intestine, it is very advantage because 5-fluorouracil the initial release it is 
required to be drastically minimized to avoid the sight effects associated with these 
agents. 
Ujwala A Shinde, Mangal S Nagarsenker., et al. (2009) A gelatin and sodium 
alginate complex coacervation system was studied and an effect of pH and colloid 
mixing ratios on coacervation was investigated. A colloid mixing ratio at which 
optimum coacervation occurred varied with the coacervationpH.Viscometric, 
turbidity and coacervate dry yield investigations were used to investigate optimum 
conditions for complex coacervation. Optimum coacervation occurred at pH 3.5 at a 
gelatin sodium alginate ratio 4:1. Coacervate and equilibrium fluid was analyzed for 
gelatin and sodium alginate contents and yields calculated on the basis of chemical 
analysis showed that optimum coacervation occurred 0at 25% sodium alginate 
fraction at pH 3.5. 
SONIA GUPTA, PMS BEDI, NEENA BEDI., et al. (2010)  
Various  formulations  of  pectin  matrix  tablets  containing  5Fluorouracil  (5FU)  
coated with combination of Eudragit RS100 and inulin were prepared and evaluated  
for release of drug in the colon, which is a prerequisite for the effective treatment of  
colorectal carcinoma. In vitro dissolution studies of formulations F1, F2, F3 and F4  
containing 30%, 45%, 60% and 75% by weight of pectin respectively revealed that  
formulations F1, F2, F3 and F4 released the entire drug after 3, 4, 6 and 11 hours of 
 the study. The cumulative percentage release data of formulations F5, F6, F7, F8 and 
F9 containing 75% by weight of pectin in the matrix coated with combination of  
Eudragit RS 100 and inulin in the ratio of 100%, 90%: 10%, 80%: 20%, 70%: 30%  
and 60%: 40% revealed that F9 is the best formulation as it released only 13.2±3.21%
 of drug after 5 hours. To further retard the initial release, formulations F10 and F11 
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 were coated to obtain a weight gain of 10.85% and 12.91% of total weight of tablets 
 respectively. Formulation F11 showed the best release data as it released 8.5±2.58% 
of drug after 5 hrs, which was less than that released by other formulations. The comp
lete drug release from formulation F11 was further tested in vitro in the presence of  
rat caecal contents and it was observed that 87.1±3.5% of drug was released after  
24 hrs in the presence of rat caecal content. 
Vaghani SS, JivaniNP., et al. (2011)  
In the present investigation, 5-fluorouracil loaded microspheres of Eudragit (RS 100, 
RL 100 and RSPO) and ethylcellulose were prepared. “O/O solvent evaporation” 
technique was used for preparation of microspheres using (methanol + acetone)/liquid 
paraffin system. Magnesium stearate was used as the droplet stabilizer and n-hexane 
was added to harden the microspheres. The prepared microspheres were characterized 
for their micromeretic properties and entrapment efficiency; as well by Fourier 
transform infrared spectroscopy (FTIR) and thin layer chromatography (TLC). 
Photomicrographs were taken to study the shape of microspheres. The best fit release 
kinetics was achieved with Higuchi plot. Mean particle size, entrapment efficiency 
and production yields were highly influenced by the type of polymer and polymer 
concentration. It is concluded from the present investigation that various Eudragit and 
Ethylcellulose are promising controlled release carriers for 5-FU. 
Ziyaur Rahman, KanchanKohli.et al (2006) 
The purpose of this investigation was to prepare and evaluate the colon-specific 
microspheres of 5-fluorouracil for the treatment of colon cancer. Core microspheres 
of alginate were prepared by the modified emulsification method in liquid paraffin 
and by cross-linking with calcium chloride. The core microspheres were coated with 
Eudragit S-100 by the solvent evaporation technique to prevent drug release in the 
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stomach and small intestine. The microspheres were characterized by shape, size, 
surface morphology, size distribution, incorporation efficiency, and in vitro drug 
release studies. The outer surfaces of the core and coated microspheres, which were 
spherical in shape, were rough and smooth, respectively. The size of the core 
microspheres ranged from 22 to 55 µm, and the size of the coated microspheres 
ranged from 103 to 185 µm. The core microspheres sustained the drug release for        
10 hours. The release studies of coated microspheres were performed in a pH 
progression medium mimicking the conditions of the gastrointestinal tract. Release 
was sustained for up to 20 hours in formulations with core microspheres to a Eudragit 
S-100 coat ratio of 1:7, and there were no changes in the size, shape, drug content, 
differential scanning calorimetrythermogram, and in vitro drug release after storage at 
40°C/75% relative humidity for 6 months. 
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4.2. DRUGPROFILE 
(Indian Pharmacopoeia, 2007) 
(www.Fluorouracil - Wikipedia, the free encyclopedia.html) 
(www.fluorouracil/DrugBank  Fluorouracil (DB00544).html) 
Fluorouracil is a pyrimidine analog that is an antineoplastic ant metabolite. It 
interferes with DNA synthesis by blocking the thymidylate synthetase conversion of 
deoxyuridylic acid to thymidylic acid. 
DRUG NAME: 5- Fluorouracil  
Molecular structure: 
 
Molecular formula: C4H3FN2O2.  
Molecular weight: 130.077 g/mol. 
IUPAC Name:5-fluoro-1H-pyrimidine-2, 4-dione... 
CAS NUMBER: [51-21-8].  
Melting point: 282-286ºc  
Physical properties: 
 It is a white crystalline powder, odorless in nature. Soluble in water, partially 
soluble in cold water, methanol and soluble in diethyl ether. 
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Mechanism of action:  
       The precise mechanism of action has not been fully determined, but the main 
mechanism of fluorouracil is thought to be the binding of the deoxyribonucleotide of 
the drug (FdUMP) and the folate cofactor, N5–10-methylenetetrahydrofolate, to 
thymidylate synthase (TS) to form a covalently bound ternary complex. This results in 
the inhibition of the formation of thymidylate from uracil, which leads to the 
inhibition of DNA and RNA synthesis and cell death. Fluorouracil can also be 
incorporated into RNA in place of uridine triphosphate (UTP), producing a fraudulent 
RNA and interfering with RNA processing and protein synthesis. 
Pharmacokinetics: 
Absorption: 28-100% 
Distribution: Into all body water by passive diffusion, crosses placenta, BBB, high 
and persistent levels in malignant effusions. 
Protein binding: 8 to12% 
Metabolism: Hepatic metabolism. 
Excretion:  
             Seven percent to 20% of the parent drug is excreted unchanged in the urine in 
6 hours; of this over 90% is excreted in the first hour. The remaining percentage of 
the administered dose is metabolized, primarily in the liver. 
Half life: 10 to 20 min. 
Indications:  
             5-fluorouracil is one of the oldest and best antineoplastic drug. For more than 
four decades 5-fluorouracil has been widely used in the therapy of different solid 
tumor types namely cancer of the stomach, liver, intestine, pancreas, ovary, breast 
alone or in combination chemotherapy regimes it is one of the most used for the 
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treatment of colorectal cancer, 5-fluorouracil has been in use against cancer for about 
40 years. It is used in treating colorectal cancer, and pancreatic cancer, in which it has 
been the established form of chemotherapy for decades. It is also sometimes used in 
the treatment of inflammatory breast cancer. 5-FU is also used in ophthalmic surgery, 
specifically to augment trabeculectomy (an operation performed to lower the 
intraocular pressure in patients with glaucoma). Fluorouracil can be used topically for 
the treating actinic (solar) keratoses and some types of basal cell carcinomas of the 
skin. 
Adverse effects:  
            Diarrhea, nausea, and possible occasional vomiting mouth sores, poor 
appetite, watery eyes, taste changes, discoloration along vein through which 
medication is given and low blood counts temporarily. 
             Adverse reactions include chest pain, ECG changes and increase in cardiac 
enzymes which may indicate problems with the heart. These symptoms are very rare 
but increased for patients with a prior history of heart disease. 
            Most people do not experience all of the side effects listed. Side effects are 
often predictable in terms of their onset and duration and are almost always reversible 
and will disappear after treatment is complete. 
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4.3 POLYMERSPROFILE 
4.3.1 GELATIN 
Nonproprietary Names: 
BP  :  Gelatin 
JP  :  Gelatin 
PhEur  :  Gelatin 
USP-NF :  Gelatin 
Synonyms: gelatina; gelatine; Instagel; Kolatin; Solugel; Vitagel. 
Chemical Name: Gelatin  
CAS Registry Number: [9000-70-8] 
Empirical Formula and Molecular Weight: 
Gelatin is a generic term for a mixture of purified protein fractions obtained 
either by partial acid hydrolysis (type A gelatin) or by partial alkaline hydrolysis  
(type B gelatin) of animal collagen Obtained from cattle and pig bone, cattle skin 
(hide), pigskin, and fish skin. Gelatin may also be a mixture of both types. The protein 
fractions consist almost entirely of amino acids joined together by amide linkages to 
form linear polymers, varying in molecular weight from 20,000–200,000.  
Structural Formula: 
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Functional Category: 
Coating agent, film-forming agent, gelling agent, suspending agent, tablet 
binder and viscosity-increasing agent. 
Description: 
Gelatin occurs as a light-amber to faintly yellow-colored, vitreous, brittle 
solid. It is practically odorless and tasteless, and is available as translucent sheets, 
flakes, and granules, or as a coarse powder. 
Color             : light amber to faintly yellow coloured. 
Odor  : odorless. 
Taste  : Tasteless 
Texture : brittle solid  
Acidity / Alkalinity: For a 1% w/v aqueous solution at 258C (depending on source 
And grade) 
pH = 3.8–5.5 (type A); 
pH = 5.0–7.5 (type B). 
Solubility: 
Practically insoluble in acetone, chloroform, ethanol (95%), ether, and 
methanol. Soluble in glycerin, acids, and alkalis, although strong acids or alkalis 
cause precipitation. In water, gelatin swells and softens, gradually absorbing between 
five and 10 times its own weight of water. Gelatin is soluble in water above 408ºC, 
forming a colloidal solution, which gels onCooling to 35–408ºC. This gel–sol system 
is thixotropic and heatreversible, the melting temperature being slightly higher than 
the setting point; the melting point can be varied by the addition of glycerin. 
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Stability and StorageConditions: 
Dry gelatin is stable in air. Aqueous gelatin solutions are also stable for long 
periods if stored under cool conditions but they are subject to bacterial degradation. 
At temperatures above about 508ºC, aqueous gelatin solutions may undergo slow 
depolymerization and a reduction in gel strength may occur on resetting. 
Depolymerization becomes more rapid at temperatures above 658ºC, and gel strength 
may be reduced by half when a solution is heated at 808ºC for 1 hour. The rate and 
extent of depolymerization depends on the molecular weight of the gelatin, with a 
lower-molecular-weight material decomposing more rapidly.Gelatin may be sterilized 
by dry heat. The bulk material should be stored in an airtight container in a cool,  
well-ventilated and dry place. 
Incompatibilities: 
Gelatin is an amphoteric material and will react with both acids and bases. It is 
also a protein and thus exhibits chemical properties characteristic of such materials; 
for example, gelatin may be hydrolyzed by most proteolytic systems to yield its amino 
acid components. Gelatin will also react with aldehydes and aldehydic sugars, anionic 
and cationic polymers, electrolytes, metal ions, plasticizers, preservatives, strong 
oxidizers, and surfactants. It is precipitated by alcohols, chloroform, ether, mercury 
salts, and tannic acid. Gels canbe liquefied by bacteria unless preserved. Some of 
these interactions are exploited to favorably alter the physical properties of gelatin: for 
example, gelatin is mixed with aplasticizer, such as glycerin, to produce soft gelatin 
capsules and suppositories; gelatin is treated with formaldehyde to produce gastro 
resistance. 
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4.3.2 SODIUM ALGINATE 
Nonproprietary Names: 
BP  : Sodium Alginate 
PhEur  : Sodium Alginate 
USP-NF : Sodium Alginate 
Synonyms: 
Alginatosodico, algin, alginic acid, sodium salt, E401, Kelcosol, Keltone, 
natriialginas, Protanaland sodiumpolymannuronate. 
Chemical Name: Sodium alginate  
CAS Registry Number:  [9005-38-3] 
Empirical Formula and Molecular Weight: 
Sodium alginate consists chiefly of the sodium salt of alginicacid, which is a 
mixture of polyuronic acids composed of residues of Dmannuronicacid and              
L-guluronic acid. 
Structural Formula: 
 
Functional Category: 
Stabilizing agent, suspending agent, tablet and capsule disintegrant. 
Description: 
Sodium alginate occurs as an odorless and tasteless, white to pale yellowish-
brown colored powder. 
Color  : pale yellowish-brown 
Odor  : odorless. 
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Taste  : tasteless 
Texture : powder  
Acidity/alkalinity: pH _ 7.2 (1% w/v aqueous solution) 
Solubility: 
Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water 
mixtures in which the ethanol content is greater than 30%. Also, practically insoluble 
in other organic solvents and aqueous acidic solutions in which the pH is less than 3. 
Slowly soluble in water, forming a viscous colloidal solution. 
Stability and Storage Conditions: 
Sodium alginate is a hygroscopic material, although it is stable if stored at low 
relative humidities and a cool temperature. Aqueous solutions of sodium alginate are 
most stable at pH4–10. Below pH 3, alginic acid is precipitated. A 1% w/v aqueous 
solution of sodium alginate exposed to differing temperatures had a viscosity 60–80% 
of its original value after storage for 2 years. Solutions should not be stored in metal 
containers. Sodium alginate solutions are susceptible on storage to microbial spoilage, 
which may affect solution viscosity. Solutions are ideally sterilized using ethylene 
oxide, although filtration using a 0.45 mm filter also has only a slight adverse effect 
on solution viscosity. Heating sodium alginate solutions to temperatures above 70°C 
causes depolymerization with a subsequent loss of viscosity. Autoclaving of solutions 
can cause a decrease in viscosity, which may vary depending upon the nature of any 
other substances present. Gamma irradiation should not be used to sterilize sodium 
alginate solutions since this process severely reduces solution viscosity. Preparations 
for external use may be preserved by the addition of 0.1% chlorocresol, 0.1% 
chloroxylenol, or parabens. If the medium is acidic, benzoic acid may also be used. 
The bulk material should be stored in an airtight container in a cool, dry place. 
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Incompatibilities: 
Sodium alginate is incompatible with acridine derivatives, crystal violet, 
phenyl mercuric acetate and nitrate, calcium salts, heavy metals, and ethanol in 
concentrations greater than 5%. Low concentrations of electrolytes cause an increase 
in viscosity but high electrolyte concentrations cause salting-out of sodium alginate; 
salting-out occurs if more than 4% of sodium chloride is present. 
Applications in Pharmaceutical Formulation or Technology: 
1. Sodium alginate is used in a variety of oral and topical pharmaceutical 
formulations. 
2.  In tablet formulations, sodium alginate may be used as both a binder and 
disintegrant; it has been used as a diluent in capsule formulations. 
3. Sodium alginate has also been used in the preparation of sustained-release oral 
formulations since it can delay the dissolution of a drug from tablets, capsules 
and aqueous suspensions. 
4.  The effects of particle size, viscosity and chemical composition of sodium 
alginate on drug release from matrix tablets have been described.  
5. In topical formulations, sodium alginate is widely used as a thickening and 
suspending agent in a variety of pastes, creams, and gels, and as a stabilizing 
agent for oil-in-water emulsions.  
6. Recently, sodium alginate has been used for the aqueous microencapsulation 
of drugs, in contrast with the more conventional microencapsulation 
techniques which use organic solvent systems. It has also been used in the 
formation of nanoparticles 
7. Sodium alginate is also used in cosmetics and food products 
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Table 4.1: Uses of sodium alginate. 
USE CONCENTRATION (%) 
Pastes and creams 5-10 
Stabilizer in emulsions 1-3 
Suspending agent 1-5 
Tablet binder 1-3 
Tablet disintigrent 2.5-10 
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4.3.3  ETHYL CELLULOSE 
Nonproprietary Names: 
BP  : Ethyl cellulose 
PhEur  : Ethyl cellulose 
USP-NF : Ethyl cellulose 
Synonyms: Aquacoat ECD, Aqualon, Ashacel, E462, Ethocel, ethylcellulosum 
Surelease. 
Chemical Name: Cellulose ethyl ether.  
CAS Registry Number: [9004-57-3] 
Empirical Formula and Molecular Weight:  
Ethyl cellulose is partially ethoxylated. Ethyl cellulose with complete ethoxyl 
substitution (DS = 3) is C12H23O6 (C12H22O5) nC12H23O5 where n can vary to provide 
a Wide variety of molecular weights. Ethyl cellulose, an ethyl ether of cellulose, is a 
long-chain polymer of b- anhydroglucose units joined together by acetal linkages. 
Structural Formula: 
 
Functional Category: 
Coating agent, flavoring agent, tablet binder, tablet filler,viscosityincreasing agent. 
Description: 
Ethyl cellulose is a tasteless, free-flowing, and white to light tan-colored powder. 
Color  : white to light tan-colored powder 
Odor  : odorless. 
Taste  : tasteless 
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Texture : powder  
Solubility: 
Ethyl cellulose is practically insoluble in glycerin, propylene glycol, and 
water. Ethyl cellulose that contains lessthan 46.5% of ethoxyl groups is freely soluble 
in chloroform, methyl acetate, and tetrahydrofuran, and in mixtures ofaromatic 
hydrocarbons with ethanol (95%). Ethyl cellulosethat contains not less than 46.5% of 
ethoxyl groups is freely soluble in chloroform, ethanol (95%), ethyl acetate, methanol, 
and toluene. 
Stability and Storage Conditions: 
Ethyl cellulose is a stable, slightly hygroscopic material. It ischemically 
resistant to alkalis, both dilute and concentrated, andto salt solutions, although it is 
more sensitive to acidic materialsthan are cellulose esters.Ethyl cellulose is subject to 
oxidative degradation in the presenceof sunlight or UV light at elevated temperatures. 
This may beprevented by the use of antioxidant and chemical additives thatabsorb 
light in the 230–340nm range.Ethyl cellulose should be stored at a temperature not 
exceeding 328ºC (908F) in a dry area away from all sources of heat. It shouldnot be 
stored next to peroxides or other oxidizing agents. 
Incompatibilities: 
Incompatible with paraffin wax and microcrystalline wax. 
Applications in Pharmaceutical Formulation or Technology 
 Ethyl cellulose is widely used in oral and topical pharmaceutical formulations. 
 The main use of ethyl cellulose in oral formulations is as a hydrophobic 
coating agent for tablets and granules. Ethyl cellulose coatings are used to 
modify the release of a drug, to mask an unpleasant taste, or to improve the 
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stability of a formulation. For example where granules are coated with           
ethyl cellulose to inhibit oxidation. 
  Modified-release tablet formulations may also beProduced using              
ethyl cellulose as a matrix former. Ethyl cellulose, dissolved in an organic 
solvent or solvent mixture, can be used on its own to produce water-insoluble 
films. 
 Drug release through ethyl cellulose-coated dosage forms can be controlled by 
diffusion through the film coating. This can be a slow process unless a large 
surface area (e.g. capsules or granules compared with tablets) is utilized. In 
those instances, aqueous ethyl cellulose dispersions are generally used to coat 
granules or capsules. 
 Ethyl cellulose-coated beads and granules have also demonstrated the ability 
to absorb pressure and hence protect the coating from Fracture during 
compression.  
 High-viscosity grades of ethyl cellulose are used in drug microencapsulation.  
 Release of a drug from an ethyl cellulose microcapsule is a function of the 
microcapsule wall thickness and surface area. 
  In tablet formulations, ethyl cellulose may additionally be employed as a 
binder, the ethyl cellulose being blended dry or wet granulated with a solvent 
such as ethanol (95%). 
 Ethyl cellulose produces hard tablets with low friability, although they may 
demonstrate poor dissolution. Ethyl cellulose has also been used as an agent 
for delivering therapeutic agents from oral (e.g. dental) appliances. 
 In topical formulations, ethyl cellulose is used as a thickening agent in creams, 
lotions, or gels, provided an appropriate solvent is used. Ethyl cellulose has 
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been studied as a stabilizer for emulsions. Ethyl cellulose is additionally used 
in cosmetics and food products. 
Table 4.2: Uses of ethyl cellulose. 
Use Concentration (%) 
Microencapsulation 10.0–20.0 
Sustained-release tablet coating 3.0–20.0 
Tablet coating 1.0–3.0 
Tablet granulation 1.0–3.0 
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5. MATERIALS AND EQUIPMENTS 
 
5.1. List of Materials used with Sources 
Table 5.1: List of Materials and their Suppliers 
S. 
No. Name of Material Supplied by 
1 5-fluorouracil Bindu Pharmaceuticals, Hyderabad. 
2 Gelatin Lobachemie, Mumbai.  
3 Sodium alginate Bindu Pharmaceuticals, Hyderabad. 
4 Ethylcellulose Lobachemie, Mumbai. 
5 Dil HCl Richer health care, Hyderabad. 
6 Chloroform Lobachemie, Mumbai. 
7 Na CMC Lobachemie, Mumbai. 
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5.2. List of Equipments used with model: 
Table 5.2:List of equipments with their make  
S. 
No. Name of the equipment Make 
1  Electronic balance Shimadzu, Japan 
2 UV-Visible spectrophotometer Shimadzu, Japan 
3 Standared coating pan Ganson-india 
4 FTIR Spectrophotometer Shimadzu 
5 DSC test apparatus MettlerTeldo 
6 Dissolution test apparatus  Vigo Scientifics,  Mumbai 
7 Digital pH meter  ElicoScientifics,  Mumbai 
8 Hot air oven Precision scientific co., Chennai 
9 Humidity chamber Labtech, Ambala 
10 Melting point test apparatus Precision scientific co., Chennai 
12 Phase contraction microscope Nikon 
13 SEM Merlin-FE-SEM 
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6. PRE-FORMULATION STUDIES 
 
6.1. Characterization of Drug:  
6.1.1. Colour and Appearance:                                    (Indian Pharmacopoeia, 2007) 
 The sample was observed visually. 
6.1.2.Melting Point:                                                       (Indian Pharmacopoeia, 2007) 
Melting point of drug was determined by Melting point test apparatus. 
6.1.3. Solubility:                                                           (Indian Pharmacopoeia, 2007) 
Sparingly soluble in water; slightly soluble in ethanol (95 per cent); practically 
insoluble in chloroform and in ether. 
6.1.4. Spectral Analysis of 5-fluorouracil:                   (shaik.shabbeer. et al.. 2012) 
6.1.4.1. UV Spectral Analysis of 5-fluorouracil: 
6.1.4.1.1. UV Spectral Analysis of 5-fluorouracil in methanol: 
6.1.4.1.1.1. Determination of absorption maximum in methanol: 
A stock solution of 5-fluorouracil (100µg/ml) was prepared by dissolving          
10 mg of drug in methanol and final volume was made to100ml. A dilution of          
(10 µg/ml) was kept in cuvette. The solution was scanned in the range of wavelength 
200 – 400 nm. The UV spectrum showingλmax was recorded using double beam  
UV-Visible spectrophotometer  
6.1.4.1.1.2. Preparation of Standard Curve of 5-fluorouracil in methanol: 
A stock solution of 5-fluorouracil (100 µg/ml) was prepared by dissolving            
10 mg of drug in methanol and final volume was made to 100 ml. The solutions in 
concentration range of 2-12 µg/ml were prepared by appropriate dilutions of stock 
solution. The UV absorbances of these solutions were determined spectro 
photometrically at λmax 266nm using double beam UV-Visible spectrophotometer.  
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6.1.4.1.2. UV Spectral Analysis of 5-fluorouracil by using 0.1N HCl: 
6.1.4.1.2.1. Determination of absorption maximum in 0.1N HCl: 
A stock solution of 5-fluorouracil (100 µg/ml) was prepared by dissolving            
10 mg of drug in 0.1N HCl and final volume was made to 100 ml. A dilution of 
10µg/ml was kept in cuvette. The solution was scanned in the range of wavelength 
200 – 400 nm. The UV spectrum showing λmax was recorded using double beam 
UV-Visible spectrophotometer.  
6.1.4.1.2.2. Preparation of Standard Curve of 5-fluorouracil in 0.1N HCl: 
A stock solution of 5-fluorouracil (100 µg/ml) was prepared by dissolving           
10 mg of drug in 0.1N HCl and final volume was made to 100 ml. The solutions in 
concentration range of 2 -12µg/ml were prepared by appropriate dilutions of stock 
solution. The UV absorbances of these solutions were determined spectro 
photometrically at λmax266 nm using double beam UV-Visible spectrophotometer.  
6.1.4.1.3. UVSpectral Analysis of 5-fluorouracil by using Phosphate buffer pH 6.8: 
6.1.4.1.3.1. Determination of absorption maximum in Phosphate buffer pH 6.8: 
A stock solution of 5-fluorouracil (100 µg/ml) was prepared by dissolving             
10 mg of drug in Phosphate buffer pH 6.8and final volume was made to 100 ml.            
A dilution of 10 µg/ml was kept in cuvette. The solution was scanned in the range of 
wavelength 200 - 400 nm. The UV spectrum showing λmax was recorded using 
double beam UV-Visible spectrophotometer.  
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6.1.4.1.3.2. Preparation of Standard Curve of 5-fluorouracil in Phosphate buffer 
pH 6.8: 
A stock solution of 5-fluorouracil(100 µg/ml) was prepared by dissolving 10 
mg of drug in Phosphate buffer pH 6.8and final volume was made to 100 ml. The 
solutions in concentration range of 2 - 12 µg/ml were prepared by appropriate 
dilutions of stock solution. The UV absorbances of these solutions were determined 
spectrophotometrically at λmax266 nm using double beam UV-Visible 
spectrophotometer.  
6.1.5. Infrared Spectrum:                                              (shaik.shabbeer. et al.. 2012) 
The infrared spectrum of Fluorouracil was recorded by using FTIR (Perkin 
elmer-Pharmaspec-1) instrument. A small quantity of sample was mixed with equal 
quantity of potassium bromide and placed in sample cell to record its IR spectra.  
6.1.6. Loss on drying:                                                   (Indian Pharmacopoeia, 2007) 
Loss on drying is the loss of weight expressed as percentage w/w resulting 
from volatile matter of any kind that can be driven off under specified condition. The 
test can be carried out on the well mixed sample of the substance. 
 
      Initial weight of substance – Final weight of substance 
Loss on drying =     
                                           Initial weight of substance 
 
 
6.2. Drug - polymers compatability studies: 
Drug polymers studies holds great importance in designing a formulation In 
drug formulation it is essential to evaluate the possible interactions between the active 
principle and the polymers, as the choice of the polymers should be performed in 
×100 
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relation to the drug delivery, to their compatibility with the same drug and to the 
stability of the final product. 
6.2.1. Fourier Transform Infra-Red Spectroscopy (FTIR) Study: 
(Shaik.shabbeer. et al.. 2012) 
Fluorouracil powder was mixed with various polymers in the ratio of 1:1. 
Then, the samples were scanned with FTIR (Perkin Elmer-Pharmaspec-1)over a wave 
number range of 4000-400 cm-1. 
6.2.2. Differential Scanning Calorimetry Study (DSC):  
(Shaik.shabbeer. et al.. 2012) 
Fluorouracil powder was mixed with various polymers in the ratio of 1:1. The 
mixture of drug with polymers to maximize the like hood of obscuring an interaction. 
Mixture should be examined under Nitrogen to eliminate oxidative and pyrolytic 
effect at a standard heating rate (100C/minute) on DSC. Over a temperature range, this 
will encompass any thermal changes due to the mixture of drug with polymers. 
Thermograms of pure drug are used as a reference.      
Appearance or disappearance of one or more peaks in thermograms of drug 
with polymer is considered as an indication of interaction. 
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7. FORMULATION OF MICROCAPSULES 
 
Table  7.1: Composition of microcapsules of 5-fluorouacil: 
Formulation 5-fluorouracil Na.alginate (1%) Gelatine (1%) Ethylcellulose (1%) Dil.HCl Chloroform Na cmc (1%) 
F1 150mg 50ml 50ml _ Q.s _ _ 
F2 150mg 100ml 50ml _ Q.s _ _ 
F3 150mg 200ml 50ml _ Q.s _ _ 
F4 150mg 300ml 50ml _ Q.s _ _ 
F5 150mg 500ml 50ml _ Q.s _ _ 
F6 150mg _ _ 50ml _ 25ml 100ml 
F7 150mg _ _ 100ml _ 25ml 100ml 
F8 150mg _ _ 200ml _ 25ml 100ml 
F9 150mg _ _ 300ml _ 25ml 100ml 
 
 
F1-F5 Coacervation Phase Seperation by change in pH. 
F6-F9 Emulsion Solvent Evaporation Technique 
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8. EVALUATION OF MICROCAPSULES 
 
 Evaluation of Microcapsuless: 
 Organoleptic Properties of Microcapsules. 
 Appearance. 
 Particle size. 
 Evaluation of Microcapsules. 
 Paricle size determination. 
 Percentage yield. 
 Drug content. 
 Entrapment efficiency. 
 Scanning electron microscopy. 
 Particle size distribution. 
 Zeta potential. 
 In-vitro drug release studies. 
 Release drug data model fitting. 
 Stability Studies. 
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8.1. ORGANOLEPTIC PROPERTIES OF MICROCAPSULES: 
8.1.1. Appearance:  
 Thecapsules were visually observed for physical appearance of capsules. 
8.1.2. Particle size: 
 Particle size distribution of microcapsules was determined by phase 
contraction microscopy. Few microcapsules are placed on glass slide and kept under 
the microscope.  
EVALUATION OF MICROCAPSULES:                    (shaik.shabbeer. et al.. 2012) 
8.2.1.Percentage yield: 
The dried microcapsules were weighed and percentage yield of the prepared 
microspheres was calculated by using the following formula. 
Percentage yield = (Weight of Microcapsules/Weight of Polymer + drug) X 100 
8.2.2. Drug Content: 
50 mg capsules were weighed and powdered and was transferred to a 100 ml 
volumetric flask and 15 ml pH 7.0 is added.  The drug is extracted in pH 7.0 by 
vigorously shaking the stoppered flask for 2 hrs.  Then the volume is adjusted to the 
mark with distilled water and the liquid is filtered.  The drug content was determined 
by measuring the absorbance at 266 nm after appropriate dilution. The drug content 
was calculated using the standard calibration curve.  The mean percent drug content 
was calculated. 
8.2.3. Estimation of Entrapment efficiency:       
        To evaluate the amount of the drug inside the microspheres, an indirect method 
was used. Aliquots from the filtered solutions remaining after removal of the 
microspheres were assayed spectrophotometrically. The amount of drug entrapped 
was calculated from the difference between the total amount of drug added and the 
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amount of drug found in the filtered solution. About 100 mg of microspheres were 
completely dissolved in 500 ml of phosphate buffer solutions (pH 7.4), and stirred for 
1h. Then, 2 ml of solution was filtered and the concentration of drug was determined 
spectrophotometrically by UV. Efficiency of drug entrapment was calculated in terms 
of percentage drug entrapment (PDE) as per the following formula 
                                    W initial drug – W free drug 
Percentage drug entrapment efficiency =                                                       ×100  
                       W initial drug 
 
8.2.4. Loss on drying: 
Loss on drying is the loss of weight expressed as percentage w/w resulting 
from volatile matter of any kind that can be driven off under specified condition. The 
test can be carried out on the well mixed sample of the substance. 
 
      Initial weight of substance – Final weight of substance 
Loss on drying =     
                                           Initial weight of substance 
 
 
8.2.4. Scanning electronmicroscopy: 
Morphological examination of the surface and internal structure of the dried 
beads was performed by using a scanning electron microscope (SEM). Microcapsules 
before dissolution only subjected to SEM study since, after dissolution the capsules 
become swollen palpable mass. Photographs were taken within the range of 50-500 
magnification. 
 
×100 
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8.2. IN-VITRO DRUG RELEASE STUDIES: 
8.2.1. Drug release studies in 0.1 N HCl:                       (shaik.shabbeer. et al.. 2012) 
Drug release studies were carried out by using USP dissolution type II test 
apparatus. The capsules were tested for drug release for 2 hours in 0.1N HCl (750ml) 
as the average gastric emptying time is about 2 hours. 5ml of samples were withdrawn 
at the interval of 1 hour and diluted up to 10 ml with 0.1N HCl. The absorbances were 
measured at 266 nm. Using a double beam UV spectrophotometer to find out the 
amount of 5-fluorouracil released from Microcapsules. 
8.3.2. Drug release studies in pH 6.8phosphate buffer: 
 (Shaik.shabbeer. et al.. 2012) 
After drug release studies carried out in 0.1 N HCl, then 250 ml of trisodium 
phosphate was added to the dissolution media and the pH adjusted to 6.8. Tested for 
drug release for 10 hours. 5ml of samples were withdrawn at the interval of 1 hour 
and diluted up to 10 ml with pH 6.8 phosphate buffer. The absorbance was measured 
at 266 nm, using a double beam UV spectrophotometer to find out the amount of              
5-fluorouracil released from Microcapsules. 
 
Table 8.1. Parameters for In Vitro Drug Release 
1 Apparatus USP type II apparatus (Paddle type) 
2 Temperature 37 +  0.5° C 
3 Initial Volume 900ml 
4 Speed 100 rpm 
5 Drawn volume 5 ml 
6 Running time 2 hrs in 0.1N HCl, 10 hrs in phosphate buffer 
pH 6.8  
7 Medium Replacement Media refilling at 2 hrs and 5hrs 
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8.4. RELEASE DRUG DATA MODEL FITTING:  (shaik.shabbeer. et al.. 2012)
 The suitability of several equation that are reported in the literature to identify 
the mechanisms for the release of drug was tested with respect to the release data up 
to the first 50% drug release. The data were evaluated according to the following 
equations. 
Higuchi model.  
             Mt=M0 + K0 t 
Higuchi model. 
             Mt=M0 + KH t0.5 
Korsmeyer-Higuchi model. 
             Mt=M0 + Kktn 
 Where Mt is the amount of the drug dissolved in time t. M0 is the initial 
amount of drug. K0 is the Higuchi release constant, KH is the Higuchi rate constant, 
KK is a release constant and n is the release exponent that characterizes the 
mechanism of drug release. 
8.5. STABILITY STUDIES:                              (shaik.shabbeer. et al.. 2012)
 
The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, enabling 
recommended storage conditions, re-test periods and shelf-lives. Generally, the 
observation of the rate at which the product degrades under normal room temperature 
requires a long time. To avoid this undesirable delay, the principles of accelerated 
stability studies are adopted. The International Conference on Harmonization (ICH) 
Guidelines titled “Stability testing of New Drug Substances and Products” describes 
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the stability test requirements for drug registration application in the European Union, 
Japan and the States of America. 
Stability studies were carried out at 40°C / 75% RH for the optimized 
formulation for 3 months. The microcapsules were stored at 40°C/75% RH as per 
ICH guidelines and various parameters (drug content and drug release profile) were 
monitored periodically for 3 months. 
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9. RESULTS AND DISCUSSION 
 
9.1.CHARACTERIZATION OF DRUG: 
9.1.1. Colour and Appearance: 
The drug (5-fluorouracil) colour is “White or off white Powder” as same as 
the reported reference. 
9.1.2. Melting Point: 
The Melting point of 5-fluorouracil was found to be 282ºC.  The reported 
melting point of 5-fluorouracil is 282ºC-284ºC. Hence, observed values are complies 
with IP.  
9.1.3. Solubility Study: 
The Solubility of 5-fluorouracil in different solvents is given below: 
Table 9.1: Solubility of 5-fluorouracil in Different Solvents 
 
S. No. 
 
Solvent µl 
 
Inference 
1 Acetone 130 Slightly soluble. 
2 Cold water 80 Sparingly soluble. 
3 Hot water 25 Soluble. 
4 Di methyl formamide 5 Freely soluble. 
5 DMSO 5 Freely soluble. 
6 Methanol 100 Sparingly soluble. 
7 0.1N HCl 125 Slightly soluble. 
8 pH 6.8 30 Soluble. 
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9.1.4. SPECTROSCOPIC STUDIES: 
9.1.4.1. UV Spectroscopy: 
9.1.4.1.1. Determination of λmax and Preparation of Calibration Curve of  
5-fluorouracil by using water: 
UV absorption spectrum of 5-fluorouracil in water shows λmax at 266 nm. 
Absorbance obtained for various concentrations of 5-fluorouracil in water are given in 
Table 16. The graph of absorbance concentration for 5-fluorouracilwas found to be 
linear in the concentration range of 0– 12μg /ml. The drug obeys Beer- Lambert’s law 
in the range of 0 – 12μg /ml. 
 
  
  
 
 
Fig. 9.1: Absorption maximum of 5-fluorouracil in water 
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Table 9.2: Concentration and Absorbance data for Calibration Curve of                
5-fluorouracil in methanol 
S. No. Concentrations(μg/ml) Absorbance at 266nm 
1 Blank 0 
1 2 0.0031 
2 4 0.0062 
3 6 0.0089 
4 8 0.0124 
5 10 0.0155 
6 12 0.0186 
 
 
Fig. 9.2: Calibration Curve of 5-fluorouracil in water 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 9.3. 
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Table 9.3:  Data forCalibration Curve parameters of 5-fluorouracilin methanol 
S. No. Parameters Values 
1 Slope 0.00155 
2 Intercept 0.0219 
3 Correlation coefficient (R) 0.995 
 
9.1.4.1.2. Determination of λmax and Preparation of Calibration Curve of           
5-fluorouracil by using 0.1N HCl 
UV absorption spectrum of 5-fluorouracil in 0.1N HCl shows λmax at 266 nm. 
Absorbance obtained for various concentrations of 5-fluorouracilin 0.1N HCl are given 
in Table 18. The graph of absorbance versus concentration for 5-fluorouracil was 
found to be linear in the concentration range of 0 – 12μg /ml. The drug obeys            
Beer- Lambert’s law in the range of 0– 12μg /ml. 
 
 
Fig. 9.3: Absorption maximum of 5-fluorouracil in 0.1N HCl 
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Table 9.4: Concentration and Absorbance data for Calibration Curve of                 
5-fluorouracil in 0.1N HCl 
S. No. Concentrations (μg/ml) Absorbance at 266nm 
1 Blank 0 
2 2 0.0537 
3 4 0.1131 
4 6 0.1719 
5 8 0.2321 
6 10 0.3009 
7 12 0.3601 
 
 
Fig. 9.4: Calibration curve of 5-fluorouracil in 0.1N HCl 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the Table 9.5. 
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 Table 9.5:  Data forCalibration Curve parameters of 5-fluorouracil in 0.1N HCl 
S. No. Parameters Values 
1 Slope 0.03023 
2 Intercept 0.09634 
3 Correlation coefficient (R) 0.9995 
 
9.1.4.1.3. Determination of λmax and Preparation of Calibration Curve of          
5-fluorouracil by using Phosphate buffer pH 6.8: 
UV absorption spectrum of 5-fluorouracil in pH6.8 phosphate buffer shows 
λmax at 266nm. Absorbance obtained for various concentrations of 5-fluorouracil in 
Phosphate buffer pH 6.8 are given in Table 20. The graph of absorbance versus 
concentration for 5-fluorouracil was found to be linear in the concentration range of   
2 – 12μg /ml. The drug obeys Beer- Lambert’s law in the range of 2 – 12μg /ml. 
9.1.4.1.4. Determination of λmax and Preparation of Calibration Curve of          
5-fluorouracil by using Phosphate buffer pH 6.8: 
UV absorption spectrum of 5-fluorouracil in pH7.4 phosphate buffer shows 
λmax at 266nm. Absorbance obtained for various concentrations of 5-fluorouracil was 
found to be linear in the concentration range of 2 – 12μg /ml. The 5-fluorouracil 
absorbance in Phosphate buffer pH 6.8 is given in Table 22. The graph of absorbance 
concentration for drug obeys Beer- Lambert’s law in the range of 2 – 12μg /ml. 
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Fig. 9.5: Absorption maximum of 5-fluorouracil in Phosphate buffer pH 6.8 
Table 9.6: Concentration and Absorbance data for Calibration Curve of               
5-fluorouracil in Phosphate buffer pH 6.8 
S. No. Concentration (μg/ml) Absorbance at 266nm 
1 Blank 0 
2 2 0.149 
3 4 0.3197 
4 6 0.475 
5 8 0.639 
6 10 0.799 
7 12 0.949 
 
The values of Correlation coefficient (R), Slope, Intercept obtained from the 
calibration curve are given in the following table 9.7. 
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Fig. 9.6: Calibration curve of 5-fluorouracil in Phosphate buffer pH 6.8 
 
Table 9.7:  Data for Calibration Curve parameters of 5-fluorouracil in 
Phosphate buffer pH 6.8 
S. No. Parameters Values 
1 Slope 0.037 
2 Intercept 0.0226 
3 Correlation coefficient (R) 0.9996 
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9.1.4.2. Fourier Transform Infra-Red Spectroscopy (FTIR): 
The IR spectrum of 5-fluorouracil is shown in figure 15. The Interpretation of 
IR frequencies are shown in Table 24. 
 
 
 
Fig. 9.7:  IR Spectrum of 5-fluorouracil 
 
Interpretation of IR Spectrum: 
Table 9.8 shows the peaks observed at different wave numbers and the 
functional group associated with these peaks.The major peaks are identical to 
functional group of 5-fluorouracil. Hence, the sample was confirmed as                     
5-fluorouracil.  
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Table 9.8: Characteristic Frequencies in IR Spectrum of 5-fluorouracil 
Wave nuwavenummber (cmˉ1) Functional group 
3135.32 OH Stretching 
3068.53 CH Stretching 
2928.01 CH
3
 Asymmetric stretching 
1722.84 C=O stretching 
1429.36 C=O Stretching 
1348.26 Symmetric CH
3 
vibration 
1246.17 C-O Stretching 
994.56 CH Deformation 
949.18 OH Deformation 
751.15 CH
2
 Rocking 
 
 
9.1.5. Loss on drying: 
The percentage loss on drying after 5 hours was found to be 0.208±0.003%. 
The sample passes test for loss on drying as per the limits specified in IP.  
Table 9.9: Loss on drying of 5-fluorouracil 
S. No. Percentage Loss on drying 
(%) 
Average LOD 
(%) 
1 0.205  
0.208±0.003 2 0.206 
3 0.214 
All the values are expressed as a mean ± SD., n = 3 
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9.2 DRUG - POLYMERS COMPATIBILITY STUDIES  
Fig. 9.8. Fourier Transform Infra-Red Spectroscopy (FTIR): 
 
  
A. 
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Fig.9.9. FTIR Spectrosccopy of Fluorouracil and sodium alginate 
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Fig. 9.10. FTIR Spectroscopy of fluorouracil and gelatin 
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Fig.9.11. FTIR spectroscopy of fluorouracil and ethyl cellulose 
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Fig.9.12. Dsc of 5-fluorouracil standard drug 
 
Fig.9.13. .Dsc of 5-fluorouracil + sodium alginate 
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Fig.9.14. .Dsc of 5-fluorouracil + gelatine 
 
 
Fig.9.15. .Dsc of 5-fluorouracil+ethyl cellulose 
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From the above figures, it can be seen that, the major functional group peaks 
observed in spectra’s of 5-fluorouracil with Sodium alginate, 5-fluorouracilwith 
gelatin and 5-fluorouracilwith ethyl cellulose remains unchanged as compared with 
spectra of 5-fluorouracil. So from the above IR spectra it can be observed that there is 
no interaction between 5-fluorouracil and Polymers used in the formulations. 
 
9.3. ORGANOLEPTIC PROPERTIES OF 5-FLUOROURACIL 
MICROCAPSULES: 
9.3.1. Appearance: 
Table 9.10: General appearance study of microcapsules 
Parameters F1-F5 F6-F9 
Composition Gelatin and Sodim alginate Ethyl cellulose 
Shape Spherical Spherical 
Size by visualization Large Small 
Colour Creamish white More white than control 
Stickiness None None 
Odour No No 
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9.3.1.1. Appearance: 
 The phase contraction microscope shows the capsules being spheroid in shape 
and showing smooth surface of capsules. 
 
Fig.9.16. Particle size analysis by phase contraction microscopy 
9.3.2.Particle size: 
Table 9.11: particle size for various formulations of microcapsules 
Formulations 
Code 
Particle size 
(µm ± S.D) 
F1 205.97±0.41 
F2 207.64±0.375 
F3 168.98±0.452 
F4 469.72±0.271 
F5 515.74±0.376 
F6 14.56±0.166 
F7 10.99±0.336 
F8 5.60±0.150 
F9 4.31±0.240 
All the values are expressed as a mean ± SD., n = 3 
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9.3.2.1. Particle size: 
 The size of micro capsules found to be in the range of 4.31 µm to 515.74µm 
and it was observed that increase in concentration of coating polymer particle size of 
themicro capsules significantly increased. The average particle size is highest for F9. 
Theparticle size distribution is uniform and narrow. 
9.4. EVALUATION OF 5-FLUOROURACIL MICROCAPSULES:  
Table 9.12: Physico-Chemical Properties of microcapsules: 
Formulations 
Code % Yield 
Drug 
Content* 
(%) 
% Entrapment 
F1 79.76 53.35±0.94 83.08±1.62 
F2 71.42 56.81±1.31 85.12±1.21 
F3 89.26 63.61±1.71 88.70±1.08 
F4 65.94 36.76±1.59 88.40±1.08 
F5 61.23 38.09±1.57 76.04±1.23 
F6 63.84 46.15±1.50 79.42±0.41 
F7 78.26 45.01±1.36 84.84±1.46 
F8 79.06 57.92±1.81 81.79±1.32 
F9 92.06 75.08±1.25 88.79±1.08 
All the values are expressed as a mean ±SD., n = 3 
9.4.1. . Percentage Yield, Drug Content and Entrapment Efficiency 
The percentage yield, Drug Content and Entrapment Efficiency of Sustained 
release microspheres were found to increased as the polymer ratio was increased. The 
maximum yield of microspheres was 92.06% in Ethyl cellulose  polymer, 89.26% in 
Gelatin and sodium alginate polymer. Better yield of microspheres was obtained from 
Ethyl cellulose. Drug content and Entrapment efficiency was high in Ethyl cellulose 
containing formulations when compared to gelatin and sodium alginate  formulations. 
All the formulations Percentage Yield, Drug content and Entrapment efficiency data 
was showed in Table 9.12. 
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9.4.2. Loss on drying: 
The value of loss on drying was found to be (0.208%±0.003) and obese the 
pharmacopeia limits(Less than 0.5%). 
9.4.3. Scanning electron microscope (SEM): 
 
Fig.9.17.SEM image of microcapsule 
Fig.9.17: Scanning electron microscopy of 5-fluorouracil loaded microcapsule 
The scanning electron microscope shows the capsules being spheroid in shape. 
Surface depression was noted at the point of contact on the drying paper. On 
comparison of the capsules prepared from polymers in high concentrations more 
roughness was observed with ethyl cellulose polymers. Ethyl cellulose produces more 
smooth surface area as compared to others. 
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9.4.4 Particle size distribution: 
Particle size analysis of fluorouracil loaded microcapsules was done by dynamic light 
scattering using a Malvern system and the mean particle size of fluorouracil 
microcapsules was found to be 4.31 figure shows the particle size distribution of 
fluorouracil loaded microcapsules. The polydispersity of prepared microcapsules was 
10.3. 
 
 
Fig.9.18. particle size distribution by using Malvern system 
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9.4.5.Surface charge 
 
Surface charge analysi sof the 5-Fluorouraci lloaded microcapsules 
wasdone by the Malvern Zeta sizer and the zetapotential was found to be                      
-5.60mV.Theresult of Zeta potential distribution is given in Figure 5.6 
 
 
 
Fig.9.19..Zeta potential determination by using Malvern system 
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9.5. IN-VITRO DRUG RELEASE STUDIES: 
9.5.1. IN-VITRO DRUG RELEASE PROFILE OF MICROCAPSULES: 
 Drug release Profile for Formulation F1: 
Table 9.13: In-vitro drug release data of Formulation F1 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drugRelease 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.90±0.285 5.90 0.50 5.90 
3 
pH 6.8 
phosphate 
buffer 
2 6.90±0.025 6.90 0.59 12.8 
4 3 10.93±0.025 10.93 1.24 16.83 
5 4 17.39±0.285 17.39 2.03 23.29 
6 5 20.92±0.28 20.92 2.44 26.82 
7 6 51.32±0.065 51.32 4.20 57.22 
8 7 71.45±0.03 71.45 4.84 77.35 
9 8 74.28±0.03 74.28 4.96 80.18 
10 10 75.68±0.03 75.68 5.04 81.58 
11 12 76.89±0.3 76.89 5.17 82.79 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.20. Cumulative percentage Drug release profile of F1. 
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 Drug release Profile for Formulation F2: 
Table 9.14: In-vitro drug release data of Formulation F2 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.90±0.195 5.90 0.50 5.90 
3 
pH 6.8 
phosphate 
buffer 
2 6.46±0.039 6.46 0.58 12.36 
4 3 10.07±0.025 10.07 1.22 15.97 
5 4 17±0.03 17 2.07 22.9 
6 5 20.45±0.03 20.45 2.47 26.35 
7 6 50.58±0.03 50.58 4.23 56.48 
8 7 71.63±0.03 71.63 4.89 77.53 
9 8 75.23±0.03 75.23 5.03 81.13 
10 10 76.42±0.234 76.42 5.11 82.32 
11 12 76.89±0.03 76.89 5.24 81.79 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.21. Cumulative percentage Drug release profile of F2 
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 Drug release Profile for Formulation F3: 
Table 9.15: In-vitro drug release data of Formulation F3 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.71±0.09 5.71 0.50 5.71 
3 
pH 6.8 
phosphate 
buffer 
2 6.32±0.025 6.32 0.63 12.03 
4 3 9.78±0.03 9.78 1.24 15.49 
5 4 16.12±0.025 16.12 2.10 21.83 
6 5 20.03±0.03 20.03 2.54 25.74 
7 6 55.19±0.03 55.19 4.20 60.9 
8 7 72.35±0.03 72.35 4.94 78.06 
9 8 79.86±0.025 79.86 5.09 85.57 
10 10 82.91±0.188 82.91 5.17 88.62 
11 12 88.59±0.219 88.59 5.27 94.3 
All the values are expressed as a mean ±SD., n = 3 
 
 
Fig.9.22. Cumulative percentage Drug release profile of F3 
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 Drug release Profile for Formulation F4: 
Table 9.16: In-vitro drug release data of Formulation F4 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.91±0.060 5.91 0.50 5.91 
3 
pH 6.8 
phosphate 
buffer 
2 6.62±0.0.03 6.62 0.65 12.53 
4 3 10.07±0.025 10.07 1.19 15.98 
5 4 16.70±0.032 16.70 2.00 22.61 
6 5 21.03±0.032 21.03 2.43 26.94 
7 6 49.85±0.03 49.85 4.21 55.76 
8 7 70.32±0.03 70.32 4.81 76.23 
9 8 72.62±0.03 72.62 4.94 78.53 
10 10 76.04±0.025 76.04 5.06 81.95 
11 12 79.19±0.03 79.19 5.25 85.1 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.23. Cumulative percentage Drug release profile of F4 
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 Drug release Profile for Formulation F5: 
Table 9.17: In-vitro drug release data of Formulation F5 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.27±0.08 5.27 0.50 5.19 
3 
pH 6.8 
phosphate 
buffer 
2 6.04±0.025 6.04 0.60 11.31 
4 3 9.58±0.03 9.58 1.23 14.85 
5 4 15.98±0.025 15.98 2.05 21.25 
6 5 19.73±0.025 19.73 2.48 25 
7 6 46.41±0.03 46.41 4.22 51.68 
8 7 69.04±0.03 69.04 4.86 74.31 
9 8 73.08±0.025 73.08 5.01 78.35 
10 10 74.08±0.025 74.08 5.16 79.35 
11 12 75.10±0.031 75.10 5.35 80.37 
All the values are expressed as a mean ±SD., n = 3 
 
 
Fig.9.24. Cumulativepercentage Drug release profile of  F5 
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 Drug release Profile for Formulation F6: 
Table 9.18: In-vitro drug release data of Formulation F6 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.82±0.07 5.82 0.50 5.76 
3 
pH 6.8 
phosphate 
buffer 
2 6.75±0.045 6.75 0.60 12.57 
4 3 12.10±0.025 12.10 1.21 17.92 
5 4 19.59±0.03 19.59 2.08 25.41 
6 5 24.2±0.03 24.2 2.56 30.02 
7 6 56.07±0.025 56.07 4.23 61.89 
8 7 74.66±0.025 74.66 4.88 80.48 
9 8 76.83±0.025 76.83 4.98 82.65 
10 10 78.43±0.03 78.43 5.19 84.25 
11 12 80.87±0.03 80.87 5.43 86.69 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.25. Cumulative percentage Drug release profile of F6 
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 Drug release Profile for Formulation F7: 
Table 9.19: In-vitro drug release data of FormulationF7 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.76±0.07 5.86 0.50 5.76 
3 
pH 6.8 
phosphate 
buffer 
2 6.76±0.03 6.76 0.57 12.57 
4 3 12.09±0.03 12.09 1.03 17.92 
5 4 19.59±0.03 19.59 1.79 25.41 
6 5 24.2±0.032 24.2 2.22 30.02 
7 6 56.04±0.031 56.04 4.12 61.89 
8 7 74.23±0.035 74.23 4.71 80.48 
9 8 76.88±0.03 76.88 4.87 82.65 
10 10 78.43±0.039 78.43 5.08 84.25 
11 12 80.85±0.025 80.85 5.16 86.61 
All the values are expressed as a mean ±SD., n = 3 
 
 
Fig.9.26. Cumulative percentage Drug release profile of F7 
5-FLUOROURACIL MICROCAPSULES                          RESULTS AND DISCUSSION 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR. Page 100 
 
 Drug release Profile for Formulation F8: 
Table 9.20: In-vitro drug release data of Formulation F8 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 6.36±0.102 6.36 0.50 6.36 
3 
pH 6.8 
phosphate 
buffer 
2 8.06±0.03 8.06 0.59 14.42 
4 3 11.65±0.025 11.65 1.20 18.01 
5 4 18.43±0.025 18.43 1.91 24.79 
6 5 22.33±0.03 22.33 2.33 28.69 
7 6 54.30±0.025 54.30 3.99 60.66 
8 7 74.06±0.03 74.06 4.58 80.42 
9 8 77.26±0.03 77.26 4.67 83.62 
10 10 79.58±0.485 79.58 4.87 85.94 
11 12 81.57±0.03 81.57 4.94 87.93 
All the values are expressed as a mean ±SD., n = 3 
 
 
Fig.9.27. Cumulative percentage Drug release profile of F8 
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 Drug release Profile for Formulation F9: 
Table 9.21: In-vitro drug release data of Formulation F9 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 6.05±0.02 6.05 0.50 6.05 
3 
pH 6.8 
phosphate 
buffer 
2 7.01±0.025 7.01 0.59 13.06 
4 3 11.65±0.005 11.65 1.13 17.7 
5 4 19.15±0.0251 19.15 1.88 25.2 
6 5 23.77±0.002 23.77 2.31 29.82 
7 6 55.47±0.005 55.47 3.98 61.52 
8 7 77.21±0.0057 77.21 4.59 83.26 
9 8 79.19±0.005 79.19 4.72 85.24 
10 10 82.84±0.0017 82.84 4.90 88.89 
11 12 88.27±0.03 88.27 5.02 94.63 
All the values are expressed as a mean ±SD., n = 3 
 
 
Fig.9.28. Cumulative % Drug release profile of formulation F9 
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Fig.9.29. Percentage Drug release profile of formulation F1 – F9 
The purpose of colon targeted drug delivery system is not only to protect the 
drug from being released in the physiological environment of the Stomach and 
Intestine but also to release the drug in the colon from the microcapsules formulation. 
Hence the ability of the polymers used in the formulations (F1 to F9) to retain the 
integrity of capsules in upper GIT were assessed by conducting drug release studies in 
0.1N HCl for 2 hours and pH 6.8 phosphate buffer for 10 hours (condition mimicking 
mouth to the colon transit). After completing the dissolution study in 0.1 N HCl 
(750ml) for first two hours then, 250 ml of 0.2M trisodium phosphate was added to 
the dissolution media and the pH was adjusted to 6.8.samples are withdrawn after 
regular intervals of time to evaluate the drug release. These were analyzed 
spectrophotometrically at a wavelength of 266nm. 
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The drug release from formulation F1, F2, F3, F4 and F5was found to be 
76.89%, 76.89%, 88.59%, 79.19%and 75.10% after the end of 12 hrs. This is due to 
lesser soluble of drug in the medium. 
The drug released from formulation F6, F7, F8 and F9 containing Ethyl 
cellulose 80.87%, 80.85%, 81.57% and 88.27% respectively at the end of 12 hrs. 
The drug released from formulation F9 containing Ethyl cellulose was found 
to be 88.27% at the end of 12 hrs, which is showing high percentage drug release. 
9.6. RELEASE DRUG DATA MODELING: 
9.6.1.Kineticsof in-vitro drug release: 
 The drug diffusion through most type of polymeric system is often best 
described by Fickian diffusion (diffusion exponent, n=0.5), but other process in 
addition to diffusion are important. There is also a relaxation of the polymer chain, 
which influences the drug release mechanism. This process is described as non- 
fickian or anomalous diffusion (n=0.5-1.0).  Release from initially dry, hydrophilic 
glassy polymer that swell when added to water and become rubbery, show anomalous 
diffusion as a result of the rearrangement of macromolecular chain. The 
thermodynamics state of the polymer and penetrant concentration are responsible for 
the different type of the diffusion. A third class of diffusion is case-II diffusion (n=1), 
which is a special case of non- Fickian diffusion. To obtain kinetic parameter of 
dissolution profile, data were fitted to different kinetic models. 
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Table 9.22: Different Kinetic models for Formulations F1-F9 
Code 
Zero order First order Higuchi Peppas Best 
fitting 
model 
R
2
 
K
0
 R
2
 
K
1
 R
2
 
K R
2
 
n 
F1 0.7199 0.0182 0.7203 0.0002 0.9710 0.0524 0.9554 0.3914 Higuchi 
F2 0.7284 0.0182 0.7288 0.0002 0.9709 0.0524 0.9538 0.3950 Higuchi 
F3 0.7815 0.7610 0.7540 0.0542 0.8934 0.0549 0.7133 0.2578 Higuchi 
F4 0.8484 0.6789 0.8928 0.0549 0.9395 0.0764 0.9411 0.3533 Higuchi 
F5 0.7248 0.0179 0.7252 0.0002 0.9716 0.0516 0.9558 0.3912 Higuchi 
F6 0.7423 0.0849 0.8414 0.0088 0.9441 0.2727 0.9416 0.3975 Higuchi 
F7 0.7336 0.0186 0.7340 0.0002 0.9744 0.0535 0.9621 0.4040 Higuchi 
F8 0.7371 0.0186 0.7375 0.0002 0.9730 0.0535 0.9556 0.0643 Higuchi 
F9 0.7650 0.0189 0.7653 0.0002 0.9765 0.0543 0.9593 0.3914 Higuchi 
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Fig. 9.30: Higuchi plot of formulation F1 
 
 
Fig. 9.31: Higuchi plot of formulation F2 
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Fig. 9.32: Higuchi plot of formulation F3 
 
 
 
Fig. 9.33: Higuchi plot of formulation F4 
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Fig. 9.34: Higuchi plot of formulation F5 
 
 
 
Fig. 9.35: Higuchi plot of formulation F6 
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Fig. 9.36: Higuchi plot of formulation F7 
 
 
 
Fig. 9.37: Higuchiplot of formulation F8 
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Fig. 9.38: Higuchiplot of formulation F9 
 
  
For microcapsules, an “n” value near to 0.5 indicates diffusion control and an 
“n” value near to 1 indicates relaxation or erosion control. The intermediate value 
suggests that diffusion and erosion contributes to overall release mechanism.It was 
also observed that highest correlation was found for Higuchi log time profile (R2> 
0.99), which indicates the drug release via diffusion mechanism from all formulations. 
Drug release from the formulation F9 follows the Higuchi release mechanism 
because its R2 value nearer to one. 
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9.7. STABILITY STUDIES 
From the results of the above studies it was found that formulation F9 was 
considered as the best formulation amongst the nine formulations. Hence formulation 
F9 was selected for stability studies.  
 
9.7.1. Stability studies at the end of First month (30 days): 
9.7.1.1. Content Uniformity:  
 The Percentage drug content of f9 micro capsules after one month of stability 
studies was studied. The results are within the official limits. The data is shown in 
Table 28. 
 
Table 9.23: Drug content of formulation F9 at the end of 1 month of stability 
S. No. Formulation Percentage drug content 
1. F9          74.75±0.060 
All the values are expressed as a mean ±SD., n = 3 
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9.7.1.2.In-vitro drug release study:  
 The Cumulative Percentage Drug Release from F9 microcapsules after one 
month of stability was studied.The data is shown in Table 9.24. 
Table 9.24:  In-vitro drug release data of formulation F9 
at the end of 1 month of stability 
S. 
No. Medium 
Time 
(hours) 
 Drug 
Release 
(%) 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
drug Release 
(%) 
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.71 5.71 0.50 5.71 
3 
pH 6.8 
phosphate 
buffer 
2 6.32 6.32 0.63 12.03 
4 3 9.78 9.78 1.24 15.49 
5 4 16.12 16.12 2.10 21.83 
6 5 20.03 20.03 2.54 25.74 
7 6 55.19 55.19 4.20 60.9 
8 7 72.35 72.35 4.94 78.06 
9 8 79.86 79.86 5.09 85.57 
10 10 82.91 82.91 5.17 88.62 
11 12 88.59 88.59 5.27 94.3 
 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.39. In-vitro drug releaseprofileof formulation F9   
at the end of 1 month of stability 
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9.7.2. Stability studies at the end of Second month (60 days): 
9.7.2.1. Drug content:  
 The Percentage drug content of f9 micro capsules afterTwo months of stability 
studies was studied. The results are within the official limits. The data is shown in 
Table 9.25. 
Table 9.25: Drug content of formulation F9 at the end of 2 months of stability 
Sl. No. Formulation Percentage drug content 
1. F9 74.26±0.0513 
All the values are expressed as a mean ±SD., n = 3 
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9.7.2.2.In-vitro drug release study:  
 The Cumulative Percentage Drug Release from F9 micro capsules after Two 
months of stability was studied.The data is shown in Table 9.26. 
Table 9.26: In-vitro drug releasedataof formulation F9  
at the end of 2 months of stability 
Sl. 
No. Medium 
Time 
(hours) 
% Drug 
Release 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
% drug 
Release  
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.59±0.025 0.84 0.50 5.59 
3 
pH 6.8 
phosphate 
buffer 
2 6.31±0.015 0.90 0.57 11.9 
4 3 9.77±0.010 1.19 1.03 15.36 
5 4 16.10±0.020 1.71 1.79 21.69 
6 5 19.99±0.015 2.04 2.22 25.58 
7 6 54.15±0.025 4.83 4.12 59.74 
8 7 73.33±0.025 6.42 4.71 78.92 
9 8 77.96±0.021 6.83 4.87 83.55 
10 10 81.97±0.020 7.20 5.08 87.56 
11 12 83.71±0.015 7.29 5.16 94.15 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.40. In-vitro drug releaseprofile of formulation F9  
 at the end of 2 months of stability 
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9.7.3. Stability studies at the end of Third month (90 days): 
9.7.3.1.Drug content:  
 The Percentage drug content of f9 microcapsules after Third month of stability 
studies was studied. The results are within the official limits. The data is shown 
inTable 9.27. 
Table 9.27: Drug content of formulation F9 at the end of 3 months of stability 
 Sl. No. Formulation Percentage drug content 
1. F9 73.89±0.036 
All the values are expressed as a mean ±SD., n = 3 
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9.7.3.2.In-vitro drug release study:  
 The Cumulative Percentage Drug Release from F9 micro capsules after Two 
months of stability was studied.The data is shown in Table 9.28. 
Table 9.28: In-vitro drug release data of formulation F9  
at the end of 3 months of stability. 
S. 
No. Medium 
Time 
(hours) 
% Drug 
Release 
Amount 
of drug 
released 
(mg) 
MDT 
(hrs) 
Cumulative 
% drug 
Release  
1 0.1N HCl 0 0 0.00 0.00 0 2 1 5.62 5.62 0.50 5.62 
3 
pH 6.8 
phosphate 
buffer 
2 6.35±0.015 6.35 0.57 11.97 
4 3 9.75±0.010 9.75 1.03 15.37 
5 4 16.15±0.020 16.15 1.79 21.77 
6 5 20.00±0.015 20.00 2.22 25.62 
7 6 55.22±0.025 55.22 4.12 60.84 
8 7 72.38±0.025 72.38 4.71 78 
9 8 79.89±0.021 79.89 4.87 85.51 
10 10 82.7±0.020 82.7 5.08 88.32 
11 12 88.31±0.015 88.71 5.16 93.93 
 
All the values are expressed as a mean ±SD., n = 3 
 
Fig.9.41. In-vitro drug releaseprofile of formulation F9  
at the end of 3months of stability 
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Fig.9.42. Comparisonof drugcontent for formulation F9 with initial and different 
periods of stability 
 
 
Fig.9.43. Comparison of cumulative percentage drug released at the end of 12 
hours for formulation F9with initial and different periods of stability 
 
No statistically significant differences were observed inpercentage drug 
content and cumulative percentage drug release in optimized formulation at the end of 
three months of stability studies. So it can be concluded that the formulation is stable 
for short term storage conditions. 
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10. SUMMARY AND CONCLUSION 
 
A successful Sustained drug delivery system was developed with the 
triggering mechanism that responds to the physiological conditions particular to 
colon.  
The Sustained release microcapsules of 5-fluorouracil were prepared by using 
polymers like sodium alginate, gelatin and ethyl cellulosefor the treatment of colon 
cancer. The dissolution study of F9 Microcapsules containing Ethylcellulose was 
concluded the best formulation among other formulations, which showing the most 
desired drug release. It will be considered as optimized formulation. 
The optimized formulation F9 was subjected for stability studies, the 
formulation was found to be stable in short term stability study. 
From the in-vitrodrug release data, it can be concluded that the Ethyl cellulose 
are capable of protecting the drug from being released in Stomach and in Small 
Intestine. This retardant capacity is more in F9 as compared to other formulations. 
During the in-vitro drug release study, on exposure to the dissolution fluid, the 
microcapsules slows down further seeping-in of dissolution fluids towards the interior 
of the capsules. Once the gel layer is formed the drug release takes place mainly by 
diffusion from the inner region. On reaching the colonic environment the polymeric 
layer would soluble at colonic pH and release the major amount of drug in the region 
of colon. 
5-FLUOROURACIL MICROCAPSULES   SUMMARY AND CONCLUSION 
 
ADHIPARASAKTHI COLLEGE OF PHARMACY, MELMARUVATHUR. Page 118 
 
In the in-vitro drug release study, the drug release from the microcapsules 
required a longer time in experimental conditions. But in actual use in living systems 
these limitations for pH environment and it will never be felt. Therefore the 
microcapsules will be take place completely and rapidly in the colon region. 
While analyzing the drug release pattern of the drug from the microcapsules, it 
was found that the drug release started in the early hours of study. This was due to 
change in pH. 
Out of the nine formulations, it appears that F9 has the maximum potential in 
providing controlled drug delivery.  
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11. FUTURE PROSPECTS 
 
In this work only physic-chemical characterization and in-vitro evaluation of 
5-fluorouracilmicrocapsules were done.  
1. Along with in-vitro release study in-vivo release studies are also important. So 
in future in-vivo release study using different models are required to set the in-
vitro in-vivo correlation which is necessary for development of successful 
formulation and also long term stability studies are necessary. 
2. Study the effect of various geometric shapes, in a more excessive manner than 
previous studies, extended dimensions. 
3. Design of novel polymers according to clinical and pharmaceutical need. 
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